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Abstract 
The rising surge of bacterial resistance puts an immense economic and social strain on the 
healthcare system worldwide. Unfortunately, the production of new antibiotics is 
significantly outstripped by existing therapies that are losing their effectiveness. Limitations 
associated with conventional dosage forms are one of the main contributing factors for 
increasing antimicrobial resistance. Novel nano-drug delivery systems have immense 
potential for overcoming antimicrobial resistance. This study broadly aimed to design 
advanced materials and explore nano-based strategies for preparation of self-assembling 
delivery systems to combat Staphylococcus aureus (S. aureus) and methicillin-resistant 
Staphylococcus aureus (MRSA) infections. In this study, three novel self-assembling 
systems; supramolecular amphiphilic Beta-cyclodextrin and Oleyl amine (BCD-OLA), 
supramolecular self-assembled drug delivery system (SADDs) for enhancement of 
vancomycin (VCM) delivery, and self-assembling PEGylated Fusidic acid (PEG-FA) as a 
polymer therapeutic were designed, synthesized and employed for the formulation of nano-
drug delivery systems for efficient delivery of antibiotics. All the newly synthesized systems 
were confirmed and characterized by FTIR, DSC, NMR and molecular dynamic (MD) 
simulations. The synthesized materials and the formulated delivery system were found to be 
biosafe after exhibiting cell viability above 75% in all human cell lines tested using the MTT 
assay. The formulated nano-based systems were evaluated for sizes, polydispersity indices 
(PDI), zeta potential (ZP), surface morphology, drug release, in vitro and in vivo antibacterial 
activity. The formulated BCD-OLA nanovesicles size was shown to be 119.8 ± 1.12 nm with 
a PDI of 0.220 ± 3.98, and ZP of 25.8 ± 6.96 mV. The formulated SADDs for VCM delivery 
displayed a size of 85.15 ± 0.4 nm with PDI of 0.131 ± 0.017 and ZP of -27 ± 1.3 mV. The 
encapsulation efficiency of VCM in both formulated BCD-OLA and VCM/TS nano-system 
was 40.2 ± 4.5% and 68.8 ± 2.8%, respectively. The release profile of the encapsulated drug 
from both systems was found to have sustained release over a 48 h period. The self-
assembled PEG-FA conjugate showed an average hydrodynamic diameter of 149.3 ± 0.21 nm 
with PDI of 0.267 ± 0.012 and ZP of 5.97 ± 1.03 mV. HRTEM images revealed vesicular 
structure for supramolecular BCD-OLA, and a homogenous spherical morphology for 
formulated VCM/TS and PEG-FA nanoparticels (NPs). In vitro antibacterial activity for the 
BCD-OLA nanovesicles, VCM/TS NPs and PEG-FA (NPs) showed enhancement in 
antibacterial activity by 2- to 4-fold reduction in MIC against S. aureus and MRSA when 
compared to the bare drug. Further intracellular and macrophage studies showed that VCM-
vi 
 
loaded BCD-OLA nanovesicles had an 8- and 459-fold reduction of intracellular bacteria 
compared to the bare drug, respectively. There was a 9.5-fold reduction in the MRSA load in 
mice skin treated with VCM/TS NPs in comparison with bare VCM (p = 0.0077). Human 
serum albumin (HSA) binding studies using in silico molecular docking and Microscale 
Thermophoresis showed that PEG-FA had very weak or no interaction with HSA (Kd = 
14999 µM), which could prevent bilirubin displacement and reduce side effects. In summary, 
these novel nano-drug delivery systems show potential for improving the treatment of 
bacterial infections, which will be useful for addressing the crisis of resistant bacteria and 
declining new antibiotics. The data from this study has resulted in three first-authored 
international publications. 
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction 
This chapter provides a brief background to the study which incorporates the current status of 
infectious diseases and various limitations associated with current antibiotic therapy. 
Furthermore, it emphasizes the role of nano-drug delivery systems in the advancement of 
antibiotic therapy and provides the aims, objectives, novelty and significance of the study. 
1.2 Background 
For decades before the discovery of antimicrobial agents, pathogenic microorganisms such as 
bacteria, viruses, fungi and parasites posed a significant threat to global health, resulting in 
the development of numerous life threatening diseases [1]. These microorganisms have the 
potential to spread disease directly or indirectly and from one person to another [2]. In 
addition to being a cause of mortality, infectious diseases also contribute greatly to 
opportunistic infections in immunocompromised people, which further increases the 
mortality rates [3, 4]. The rapid evolution of infectious diseases globally in both nosocomial 
and community settings has created an urgent need for newer effective therapeutic 
interventions in both developed and developing countries [5]. This evolution has also posed a 
threat to global trade, population growth and further escalated the disease burden in 
developing countries [6, 7]. Amongst various infectious diseases, bacterial infections have 
risen to be of global concern because of their significantly high numbers and severity [8]. 
Therefore, various novel strategies to circumvent the spread of infectious diseases are 
required.  
The first drug used in hospital, now call an antibiotic was initially known as pyocyanase, 
derived from Pseudomonas aeruginosa (P. aeruginosa) and prepared by Emmerich and Löw 
in 1899 (formerly Bacillus pycyaneus) [9]. However, the treatment was eventually banned 
from use due to inconsistency and toxicity of the preparation to humans. Further 
investigations confirmed the production of antibiotic substances from P. aeruginosa [10]. 
Decades later, on September 3
rd
 , 1928, a serendipitous event occurred, which led to the 
discovery of penicillin by Alexander Fleming (1929) [11]. This breakthrough was considered 
a landmark in human progress, as it saved millions of lives and significantly contributed to 
the control of infectious diseases, as they were the leading cause of human morbidity and 
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mortality for much of human history. The continued work of succeeding researchers resulted 
in the production of several new antibiotics, some of which had gone up to the patient's 
bedside. The era between the 1950s and 1970s was indeed the golden age of discovery of 
new classes of antibiotics [9] (Figure 1). However, Fleming himself was among the first 
researchers who cautioned about the potential resistance to penicillin by bacteria if  usage is 
abused during treatment [9, 12].  
 
Figure 1. Timeline for the history of antibiotics, year of discovery and year of introduction to 
the market [13]. 
Antimicrobial resistance is not new, but the number of resistant species, the geographical 
locations affected by drug resistance and the level of resistance in single species is 
unprecedented and growing [14]. Currently, multidrug-resistant (MDR) bacteria continue to 
be extremely challenging in community health care [15]. Bacteria have developed various 
ways by which they gain resistance to antimicrobials. Among those mechanisms are enzyme 
inactivation, decreased cell permeability, target protection, increased efflux due to over-
expression of efflux pumps, target overproduction and altered target site/enzyme [16, 17]. 
The statistics of infections produced by such resistant strains are growing globally. Recent 
statistics showed an estimated 700,000 annual death rate worldwide [18]. Additionally, in 
2019, bacterial resistance led to 2.8 million severe illnesses cases and 35,000 deaths in the 
United States, which is significantly higher than the previous report in 2013. Over half the 
world's population is projected to be at risk of infectious diseases, causing a disproportionate 
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disease burden [8]. The World Health Organization (WHO) has declared antimicrobial 
resistance (AMR) as one of the thirteen most urgent health challenges for the next decade 
[19]. Additionally, they estimated that by 2050, antibiotic resistance would result in 
approximately 10 million deaths, causing nearly $100 trillion global economic loss (Figure 
2) [20]. The challenge of MDR bacteria is gaining more attention as the novel coronavirus 
(COVID-19) continues to cause secondary lung infection in susceptible patients [21]. Patients 
with such infections require strong antibiotics, however, complications arise due to the 
presence of MDR bacteria. Doctors are faced with making split-second decisions, on which 
antibiotic has the greatest chance of treating each patient effectively. This reveals the 
desperate need for new innovative approaches before we hit a tipping point. 
  
Figure 2. Death from AMR infections and other causes in 2050 [22]. 
One of the most serious resistant strains of bacteria that has risen to be of global concern is 
methicillin-resistant Staphylococcus aureus (MRSA). Since its discovery in a London 
hospital in 1960, MRSA has become a superbug of global concern [23]. MRSA infections 
have contributed to serious morbidity and mortality worldwide and can cause different organ-
specific infections. The most common infections involving the skin and soft tissue, followed 
by invasive infections, such as lung abscess, pneumonia, empyema, sepsis, meningitis and 
other metastatic complications [23, 24]. A recent study by Wozniak et al. (2019) for the 
estimation of health and economic burden of AMR infections in Australian hospitals, found 
that the cost of treating MRSA patients is nearly AUD$5.5 million per year [25]. In Europe, 
MRSA accounts for over 40 % of healthcare-associated infections and has led to an excess of 
 
4 
 
EUR 380 million in-hospital costs [26, 27]. Furthermore, according to the Center for Disease 
Control and Prevention (CDC) in 2019, the cost of healthcare due to MRSA infections in the 
United States is approximately $1.7 billion annually, with an annual infection rate of 323,700 
cases in hospitals [28]. WHO has previously listed MRSA as a superbug that needs to be 
prioritized for research to develop new alternative treatments [29]. Even though vancomycin 
(VCM) is effective and considered to be the last resort for the treatment of MRSA infections, 
some emerging strains are already resistant to VCM [30]. The evolving resistance of bacterial 
strains to the available antibiotic currently in use, accompanied by the possibility of emerging 
resistance to new antimicrobial drugs, calls for an urgent need to develop novel tactics for 
treating resistant bacterial infections. 
Since the introduction of antibiotics to the market in 1945, they have been delivered via 
conventional dosage forms. These conventional dosage forms display several limitations, 
which are not due to the ineffectiveness of the antibiotics. These limitations include 
inadequate uptake at the infection site, insufficient targeting of bacteria, exposure of healthy 
cells to antibiotics, rapid degradation and elimination from the bloodstream. These factors 
lead to suboptimal therapeutic effects, side effects, increased frequency of administration and 
poor patient compliance [31-34]. These limitations also have been identified as major 
contributing factors to the development of antibiotic resistance and have led to the reduced 
period between introduction of antibiotics and the development of resistance, resulting in 
depletion of the antibiotic pipeline (Figure 3). Paradoxically, over the past three decades, the 
AMR crisis has been further compounded by pharmaceutical companies withdrawing or 
downgrading their antibiotic research and development (R&D) programs [35]. The short 
treatment courses, coupled with the possible short lifespan of an antibiotic‘s utility owing to 
the rapid development of resistance has rendered investment into research and development 
of new antibiotics insufficiently rewarding in today‘s business model [15, 35, 36]. 
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Figure 3. Novel FDA-approved antibacterial and non-bacterial drugs [37]. 
Recent nanotechnology advances have presented exciting opportunities for the production of 
new formulations based on distinct forms of nano-drug delivery systems with varying sizes, 
shapes and versatile antimicrobial properties. Nano-drug delivery systems can provide a 
promising alternative as they may not only be bactericidal, but also serve as carriers of 
antibiotics and natural antimicrobials [33, 38, 39]. Nanotechnology is confirmed to be an 
effective strategy in enhancing antibacterial activity, protecting the antibiotics in the market 
and addressing the problems of bacterial resistance, with some antibacterial nano-drug 
delivery systems already in the market [33, 40, 41]. These various nanoantibiotics offer 
several advantages, such as i) targeting the site of infection, ii) preventing exposure of the 
drug to healthy cells, iii) enhanced solubility, iv) sustained and controlled drug release, v) 
uniform distribution of the drug in the target tissue, and vi) improved cellular 
internalization.[42, 43]. Moreover, the required effective dose can be significantly reduced by 
enhancing the pharmacokinetic profile and therapeutic index of the encapsulated drugs as 
opposed to free drugs. This advantage can, in turn, reduce the toxicity and adverse side 
effects associated with high systemic drug and frequent dosing [44, 45]. Antibiotics such as 
vancomycin, fusidic acid, teicoplanin, linezolid, daptomycin, clarithromycin, amongst others, 
have been encapsulated into various nano-systems to overcome MRSA infections [34, 46, 
47]. However, the application of nanotechnology for antibiotic therapy is still in its early 
stages compared to other medical conditions, such as cardiovascular disease and cancer [33, 
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48]. Therefore, to address the limitations associated with conventional dosage forms of 
antibiotics and the growing bacterial resistance to antibiotics, novel nano-antibiotic 
approaches are necessary. 
Amongst various nanoparticulated systems, self-assembling amphiphiles designed through 
conjugation of hydrophilic and hydrophobic components via chemical modification or 
physical interaction, are considered to be one of the most prominent and promising 
candidates for drug delivery applications [49-51]. Under aqueous conditions, the amphiphiles 
can self-assemble to form various nano-aggregates, such as vesicles, micelles, spheres, 
lamellae, rods and other complex structures [52]. In addition to all advantages of nano-
carriers, self-assembled amphiphiles have two unique attributes that make them superior in 
drug delivery. Firstly, they have the ability to assume complex structures that are difficult to 
attain via chemical synthesis. Secondly, the dissociation of self-assembled structures can be 
triggered by external stimuli, which can serve as a mechanism of payload release [53]. Also, 
more precise concentrations of drugs can be directly encapsulated within the self-assembled 
structure [54]. Self-assembled amphiphiles offer an attractive alternative to crosslinked 
polymers, rubbers, and metallics. Currently, there are commercially available therapeutics 
based on self-assembled amphiphiles [54]. Most reports for self-assembling delivery systems 
focus on anticancer research, rather than drug delivery for the treatment of antibiotic 
resistance.  Due to their unique structure and extraordinary functions, which have been 
exploited as therapeutic and diagnostic agents [55, 56], self-assembling amphiphiles are 
promising systems that can aid in restoring the effectiveness of existing antibiotics. 
Moreover, a self-assembling system with intrinsic antibacterial activity was shown to expand 
the spectrum of currently available antibiotics [57, 58]. In the present work, we have 
developed three self-assembling drug delivery systems to effectively target and treat 
methicillin-susceptible and resistant S. aureus infections; namely i) supramolecular 
amphiphiles of Beta-cyclodextrin and Oleyl amine (BCD-OLA), ii) supramolecular Self-
assembled Drug Delivery System (SADDs) of Vancomycin and Tocopherol Succinate 
(VCM/TS) as an antibacterial agent and iii) Pegylated Fusidic acid (PEG-FA) as a self-
assembling polymer therapeutic.  
Cyclodextrins (CDs) are cyclic oligosaccharides covalently connected by α(1–4) ether 
linkages, derived from bacterial degradation of starch [59, 60]. The most popular CDs are α-, 
β- and γ-CD, which are composed of six, seven and eight units of glucose, respectively [60-
62]. Owing to its solubilizing properties, low toxicity and low inflammatory response, CDs 
 
7 
 
are widely used as excipients in pharmaceutical formulations [63]. The hydrophobic inner 
cavity and the external hydrophilic surface of CDs with their ability to interact with different 
molecules make CDs extremely desirable for use in the delivery of drugs [64-68]. The 
complexation of CDs with hydrophobic compounds creates supramolecular amphiphiles via 
chemical modification [69] or host-guest interaction using their hydrophobic cavities through 
non-covalent bonds, which can self-assemble to form various nanoparticles (NPs) such as 
monolayers, micelles, bilayer vesicles, or liquid-crystalline NPs [70]. Vesicles derived from 
the self-assembly of supramolecular amphiphiles can mimic the biological membrane and 
simultaneously regulate the release of the encapsulated drug [71]. The majority of 
amphiphilic CDs derivatives used in the delivery of drugs were synthesized by chemical 
modification of CDs [72]. Complexes of CDs have been introduced for several applications 
such as drug delivery, antimicrobial coatings on devices (e.g. biomedical instruments and 
implants) and antimicrobial dressings that help avoid wound infections [63, 73, 74]. 
Interestingly, CDs are recognized as ‗trojan horses‘ for antibacterial drugs [75, 76], while 
OLA is an unsaturated fatty amine derived from the fatty acid, oleic acid, which have been 
used to synthesize various NPs as a solvent and reducer agent [77]. Furthermore, OLA has 
shown to have intrinsic antimicrobial activity and has been used for synthesis of intracellular 
delivery systems [78, 79]. The use of a nano-delivery system with intrinsic antibacterial 
activity has been shown to broaden the range of antibiotics currently available [57], thereby 
showing potential for combating antibacterial resistance. Therefore, the production of simple 
CD-amphiphiles with OLA via inclusion complexation will result in a superior drug delivery 
system with inherent antimicrobial activity and little or no toxicity. This will serve as a highly 
useful tool for combating antimicrobial resistance. Although there are many analogous drug 
delivery systems of BCD and hydrophobic guest molecules [80, 81], to the best of our 
knowledge, there have been no reports of this cationic amphiphile (BCD-OLA) for the 
delivery of any class of drug using this novel material. Despite the reported uses of BCD as a 
stabilizer for magnetic NPs through inclusion complex with surface bound OLA and oleic 
acid [82],  there have been no reports on such cationic amphiphiles with self-assembling 
properties without chemical modification of the original structure of the parent compounds. 
Amphiphilic conjugation, whereby the drug forms the building blocks of the delivery system, 
results in self-delivery with significant enhanced drug activity and loading efficiency without 
the use of non-therapeutic carriers [58, 83, 84]. However, this strategy is still dependent on 
chemical modifications of the drug, which relies on the use of toxic reagents and organic 
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solvents. Recently, a new strategy to build SADDs by producing NPs composed only of 
therapeutic molecules without any chemical bonds, based on supramolecular interactions was 
developed [85-88]. This technique focuses on producing complex structures assembled from 
molecular subunits through weak interactions, such as hydrophobic-hydrophilic bonds, 
hydrogen-bonding, metal-ligand coordination, π–π stacking and van der Waal‘s (vdW) forces 
[89]. These supramolecular complexes are identified by their unique structure and 
extraordinary functions [90], which make them useful in building advanced biomaterials [55, 
56]. Such biomaterials have been employed as therapeutic and diagnostic agents, including 
the production of new antibacterial compounds [91]. One of the last resort treatments being 
used for MRSA is the glycopeptide antibiotic, vancomycin (VCM) [92]. These bacteria have 
acquired resistance to a number of antibiotics due to improper use, inactivation of the drug 
through hydrolysis or chemical modification, genetic mutation. This has resulted in 
modification of the drug's target and reduced intracellular accumulation of the antibiotic due 
to increased cell wall thickness or over-expression of efflux pumps[93, 94]. Efflux pumps 
have been pointed out as major contributors to multidrug resistance in gram-positive and -
negative bacteria, as they extrude a wide variety of toxic compounds, including antibiotics 
from bacterial cells [95, 96]. Based on these facts, a delivery system comprising of 
compounds with the ability to interact with and/or inhibit these efflux pumps and lower the 
minimum inhibitory concentration (MIC) of the antibiotic, can be considered a promising 
therapeutic agent that will aid in restoring the effectiveness of existing antibiotics [97-99]. D-
α-tocopherol succinate (TS) is an FDA approved derivative of α-tocopherol, which is known 
also as vitamin E. Tocopherol is known for its high lipid solubility and ability to modify the 
permeability of bacterial cell membranes, causing damage in the essential elements and 
collapse of proton pumps, leading to enhanced permeability and intracellular accumulation of 
various substances, including antibiotics [100, 101]. Therefore, recent studies have tested the 
potential of α-tocopherol as an efflux pump inhibitor [101, 102]. Interestingly, the use of α-
tocopherol in combination with antibiotics has been described to enhance the sensitivity of 
drug-resistant bacteria to antibiotics [102-105], thus highlighting the usefulness of this 
compound for the development of innovative antibacterial-resistant preparations. Therefore, 
we are reporting a novel SADDs, composed of TS as the hydrophobic component and VCM 
as the hydrophilic element (VCM/TS complex), that will self-assemble into NPs; and we 
explore its potential for enhancing the antibacterial activity of VCM against S. aureus and 
MRSA. This is the first SADD formulation with TS for any class of drug, and the first SADD 
formulation with VCM. 
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Another vital part of modern therapeutics, which also forms part of nanomedicine, is 
―polymer therapeutics‖. This is a branch of drug delivery using polymers that covalently bind 
to a drug, such as poly(ethyl)ene glycol (PEG) [106]. Furthermore, polymer therapeutics that 
have the ability to self-assemble into nanosized particles have shown to be efficient in drug 
delivery. PEGylation has been reported to be a suitable technique for formulating polymer 
therapeutics. with several products such as Pegasys
®
, Mircera
®
 and Cimzia
®
 already available 
in the market [107].  PEGylated polymer therapeutics have shown to enhance the water 
solubility of poorly soluble drugs, reduce uptake by the reticulo-endothelial system, target the 
delivery of drugs to specific sites of action and reduce human serum albumin (HSA) binding 
[47, 108, 109]. Consequently, PEGylation seems to be a promising technique for modifying 
the therapeutic performance of antibiotics and overcoming bacterial resistance [110, 111]. 
There are several reports supporting the improvement of antibiotic delivery through 
polymeric conjugation, including penicillin [112, 113], fluoroquinolones [114-117], 
aminoglycoside [110, 118] and sulfonamides [119]. Fusidic acid (FA) is an antibiotic 
belonging to the fusidane group, which was first isolated from Fusidium coccineum fungus in 
1962 [120]. FA is available in different conventional dosage forms, including; tablets and 
suspension for oral, cream and ointment for topical and also for intravenous administration 
[121]. The poor water solubility and the high affinity of HSA binding of FA limit its 
formulation and therapeutic efficacy [121, 122]. Although, there have been reports of FA 
conjugation with small molecules in order to enhance and broaden its spectrum [123, 124], 
there are no reports on polymer FA conjugation to form a self-assembling polymer 
therapeutic. Therefore, polymeric conjugation of FA with a biodegradable polymer such as 
PEG, can potentially enhance the solubility, bioavailability as well as antimicrobial activity 
of FA. 
1.3 Problem statement 
Antibiotic resistance has significantly threatened the management of infectious diseases. 
Moreover, it has rendered many antibiotics ineffective towards specific bacterial strains. This 
has led to a rise in mortality and morbidity rates, especially in developing countries. Current 
drug delivery formulations present many drawbacks, such as insufficient concentration of 
drugs at infection/target sites, exposure of the drug to healthy cells, rapid degradation and 
limited bloodstream circulation which lead to suboptimal therapeutic effects, serious side 
effects, poor patient compliance and drug resistance. All of these factors suggest the immense 
need for the production of novel therapeutic compounds and approaches to curb the increase 
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in drug resistance. Nano-drug delivery systems are showing significant potential for 
overcoming the limitations associated with conventional dosage forms. The identification of 
novel nano-based strategies to enhance antibacterial activity and to target infection sites, can 
therefore, contribute to enhancing patient therapy and disease treatments. The design and 
synthesis of advanced materials and nano-based strategies for developing self-assembling 
nano-carriers are necessary to improve the antibacterial activity of currently available 
antibiotics. Furthermore, synthesis of novel self-assembling amphiphiles having inherent 
antibacterial effects and their investigation as nano-carriers to improve the activity of 
antibiotics remain to be explored.  
1.4 Aims and objectives of this study 
The broad aim of this study was to design advanced materials and explore nano-based 
strategies for preparations of self-assembling delivery systems to treat S. aureus and MRSA 
infections. The specific research aims of the three novel nano-formulations developed in this 
study for enhancing antibacterial activity are further highlighted, with their respective 
objectives. 
Aim 1 
This study aimed to synthesize and formulate a novel supramolecular amphiphile, BCD-
OLA, via inclusion complexation for the enhancement of VCM delivery. 
To achieve this aim, the objectives of the study were to: 
1. Use a single step synthetic method to form the supramolecular inclusion complex for 
synthesis of BCD-OLA amphiphile. 
2. Determine the stoichiometry of BCD-OLA complexes using Job‘s method. 
3. Characterize BCD-OLA using structural elucidation techniques such as Fourier 
transform-infrared spectroscopy (FT-IR), 
1
H NMR and 2D NMR (NOESY spectrum). 
4. Determine the in vitro cytotoxicity of the synthesized BCD-OLA to confirm its safety 
in biological systems. 
5. Formulate VCM-loaded nanovesicles from BCD-OLA amphiphile and evaluate the 
formulated nanovesicles in terms of size, polydispersity index (PDI), zeta potential 
(ZP), morphology, entrapment efficiency, in vitro drug release, flow cytometry, in 
vitro antibacterial activity and bacterial killing kinetics. 
6. Perform molecular dynamics (MD) simulations to understand the molecular 
mechanism of the inclusion complex and nanovesicle‘s formation. 
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7. Determine the efficacy of the VCM-loaded BCD-OLA nanovesicles in eradicating 
intracellular MRSA in macrophages (TPH-1) and human embryonic kidney (HEK 
293) cells.  
Aim 2 
This study aimed to synthesize and formulate a SADDs composed of two components, 
hydrophobic TS and hydrophilic VCM, as well as to explore its potential for enhancing the 
antibacterial activity of VCM against S. aureus and MRSA. 
To achieve this aim, the objectives of the study were to: 
1. Use the solvent evaporation method to screen different ratios of TS and VCM to form 
NPs with the desirable size, PDI, ZP and loading capacity. 
2. Determine the in vitro cytotoxicity and haemolytic effect of the synthesized VCM/TS 
NPs to confirm its safety in biological systems. 
3. Perform MD simulations to understand the mechanism of the complex and self-
assembly into NPs. 
4. Determine the structural change in VCM and TS before and after self-assembly into 
NPs using FT-IR and differential scanning calorimetry (DSC). 
5. Evaluate the formulated VCM/TS NPs in terms of size, PDI, ZP, morphology, 
entrapment efficiency, in vitro drug release, in vitro and in vivo antibacterial activity. 
6. Investigate the potential of TS to block the outer membrane channel of NorA and 
NorB efflux pumps and possibly prevent extrusion of antibiotics via MD simulations. 
Aim 3  
This study aimed to synthesize and formulate a novel PEGylated fusidic acid (PEG-FA), 
conjugated through a small spacer with an amide bond and to explore its potential for 
simultaneously enhancing the solubility and antimicrobial activity of FA and lowering its 
binding to HSA.  
 
To achieve this aim, the objectives of the study were to: 
1. Synthesize PEG-FA conjugate and confirm its structure using structural elucidation 
techniques such as FT-IR, 
1
H NMR, and DSC. 
2. Determine the in vitro cytotoxicity and haemolytic effect of the synthesized PEG-FA 
to confirm its safety in biological systems. 
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3. Evaluate the formulated PEG-FA NPs in terms of size, PDI, ZP, and morphology. 
4.  Evaluate the enhancement in water solubility and in vitro antibacterial activity 
compared to the bare FA. 
5. Perform MD simulations to understand the mechanism of PEG-FA self-assembly. 
6. Determine the binding affinity of FA, bilirubin and PEGylated FA molecules with 
HSA using Microscale Thermophoresis (MST) and molecular docking studies. 
1.5  Novelty of the Study  
The novelty of the project for the three experimental studies is presented hereunder.  
Aim 1 
The experimental research performed in this study, which is presented in Chapter Two, is 
novel for the following reasons: 
 There are several reports of amphiphilic CDs synthesized via chemical modification. 
This study reports the first amphiphilic CDs coined from BCD and OLA via inclusion 
complexation that are able to self-assemble into nanovesicles. 
 This is the first nanovesicle assembled from cationic amphiphile (BCD-OLA) for the 
delivery of any class of drug. 
 This is the first supramolecular complex with inherent antibacterial activity for the 
delivery of antibiotics. 
 Intracellular bacterial infections are difficult to treat, as bare drugs do not penetrate 
effectively into the cells. Intracellular bacteria use acidic phagolysosomes and 
endosomes as reservoirs. There have been several reports to address this problem 
using nano-drug delivery systems. This paper reports for the first time the targeting of 
intracellular bacterial infections using amphiphilic supramolecular complex, which 
has never been reported before. 
Aim 2 
The experimental research performed in this study, which is presented in Chapter Three, is 
novel for the following reasons: 
 This study reports the first SADDs formulated with TS for any class of drug. 
 This is the first SADD formulation of VCM. 
 This is the first report of the potential of TS to block the outer membrane channel of 
NorA and NorB bacterial efflux pumps and the binding potential of TS to NorA and 
NorB efflux pumps at a molecular level via MD simulations. 
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 This study reports the first antibacterial SADDs formulation, that has been 
characterized and confirmed to have antibiofilm activity compared to the bare drug. 
Aim 3 
The experimental research performed in this study, which is presented in Chapter Four, is 
novel for the following reasons: 
 This is the first report of FA conjugation with a biodegradable polymer. 
 This is the first self-assembling polymer therapeutic of FA. 
 This research is the first report of the quantitative binding of FA, bilirubin and 
PEGylated FA molecules with HSA using MST. 
1.6 Significance of the study 
The nano-drug delivery systems developed in this study are novel and can contribute to 
overcoming the problems of bacterial resistance to antibiotics and limitations associated with 
their conventional dosage forms. The significance of this study are highlighted below: 
New pharmaceutical products: The proposed BCD-OLA, VCM/TS and PEG-FA are new 
pharmaceutical products not yet reported in the literature. They have the potential to stimulate 
the local pharmaceutical industries to manufacture cost-effective superior medicines. 
Improved patient therapy and disease treatment: The proposed formulations can improve 
both patient therapy and treatment of various diseases associated with bacterial infections by 
enhancing antibacterial performance, minimizing doses, lowering side effects and improving 
patient compliance. Hence, it will lead to improving the quality of patients life and saving 
lives. 
Creation of new knowledge to the scientific community: These studies proposed can lead to 
new knowledge being generated in pharmaceutical sciences. It can include the following:  
 Synthesis schemes for new materials, preparation procedures for the novel drug 
delivery systems and their in vitro, in silico and in vivo properties will be identified. 
 The detailed MD simulations for self-assembly of amphiphilic materials into nano-
systems can contribute to a better mechanistic understanding of nano-formulations. 
 The combined effects of these novel antibacterial materials with antibiotics can 
identify the synergistic or additive antibacterial effects. 
 The extensive in vivo testing of these novel systems can provide knowledge for in 
vitro in vivo correlations.  
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Stimulation of new research: The proposed BCD-OLA, VCM/TS, and PEG-FA as strategies 
to improve activity against methicillin-susceptible and resistant S. aureus infections, can 
stimulate further studies on their clinical evaluation, potential for other applications and 
design of new materials. 
 
1.7 Overview of dissertation 
The research work performed is presented in this thesis in the publication format, 
according to University of Kwa-Zulu Natal, College of Health Sciences guidelines. It 
specifies the inclusion of a brief introductory chapter, published papers and a final chapter 
on the conclusions. A Ph.D. study requires at least three first-authored papers, two of 
which must be experimental. 
CHAPTER TWO: EXPERIMENTAL PAPER ONE: This chapter addresses Aim 1, 
Objectives 1-7 and is a first-authored experimental article published in an ISI 
International Journal: International Journal of Pharmaceutics (Impact Factor = 4.320). 
This article highlights the formulation of the novel amphiphilic BCD-OLA 
supramolecular complex, the in vitro toxicity evaluation and formulation of the BCD-
OLA nanovesicles to deliver VCM. It also highlights the molecular dynamics simulation 
of the self-assembly of nanovesicles, characterization of its physical properties, in vitro 
antibacterial properties and eradication of intracellular MRSA in macrophages and HEK 
293 cells. 
CHAPTER THREE: EXPERIMENTAL PAPER TWO: This chapter addresses Aim 
2, Objectives 1–6 and is a first-authored experimental article published in an ISI 
international journal: Pharmaceutical Development and Technology (Impact Factor 
2.374). This article highlights the formulation development of the novel SADDs through 
supramolecular complexation to deliver VCM, the in vitro toxicity evaluation, molecular 
dynamics simulation of the self-assembly of NPs, characterization of its physical 
properties, in vitro and in vivo antibacterial properties. 
CHAPTER FOUR: EXPERIMENTAL PAPER THREE: This chapter addresses Aim 
3, Objectives 1–6 and is a first-authored experimental article accepted in Journal of 
Biomolecular Structure & Dynamics (Impact Factor 3.22) an ISI international journal 
(manuscript ID: TBSD-2020-1529). This article highlights the synthesis of a novel 
polymeric conjugation of FA with a biodegradable polymer; PEG, the in vitro toxicity 
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evaluation, molecular dynamics simulation of the self-assembly of NPs, characterization 
of its physical properties, binding check for FA, bilirubin and PEG-FA molecules with 
HSA using MST, and in vitro antibacterial properties. 
CHAPTER FIVE: CO-AUTHORED PAPERS: In addition to the first authored 
experimental papers in Chapters, 2, 3 and 4 focusing on aims 1, 2 and 3, I have also been 
involved in other papers within our group as a Ph.D. student. As these papers also focused 
on the broad aim of this PhD project to improve treatment of bacterial infections, these 
papers have been included in the thesis. This chapter therefore includes published one 
experimental paper and one review article in an ISI International Journals: Colloids and 
Surfaces B: Biointerfaces (Impact Factor = 3.973) and WIREs Nanomedicine & 
Nanobiotechnology (Impact Factor = 7.689). 
CHAPTER SIX: CONCLUSION: This chapter includes the overall conclusions from 
research findings in the study, provides information on the potential significance of the 
findings and makes recommendations for future research work in the field of strategic 
solutions to combat bacterial resistance to antibiotics. 
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CHAPTER 2, EXPERIMENTAL PAPER 1 
3.1 Introduction 
This chapter addresses Aim 1, Objectives 1 - 7 and is a first-authored experimental 
published in an ISI International Journal: International Journal of Pharmaceutics (Impact 
Factor = 4.320). This article highlights the formulation of the novel amphiphilic BCD-
OLA supramolecular complex, the in vitro toxicity evaluation and formulation of the 
BCD-OLA nanovesicles to deliver VCM. It also highlights the molecular dynamics 
simulation of the self-assembly of nanovesicles, characterization of its physical 
properties, in vitro antibacterial properties and eradication of intracellular MRSA in 
macrophages and HEK 293 cells. 
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CHAPTER 3, EXPERIMENTAL PAPER 2 
4.1 Introduction 
This chapter addresses Aim .2, Objectives 1 - 6 and is a first-authored experimental 
article published in Pharmaceutical Development and Technology (Impact Factor 2.374), 
an ISI international journal (doi:10.1080/10837450.2020.1797786). This article highlights 
the formulation development of the novel SADDs through supramolecular complexation 
to deliver VCM, the in vitro toxicity evaluation, molecular dynamics simulation of the 
self-assembly of NPs, characterization of its physical properties, in vitro and in vivo 
antibacterial properties. 
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Abstract 
In this study self-assembled drug delivery system (SADDs) composed of a hydrophobic D-α-
tocopherol succinate (TS) and a hydrophilic vancomycin (VCM) were formulated, and its 
potential for enhancing the antibacterial activity of VCM against Staphylococcus aureus (SA) 
and Methicillin-resistant Staphylococcus aureus (MRSA) were explored. The SADDs were 
synthesized via supramolecular complexation, then characterized for in silico, in vitro and in 
vivo studies. In silico studies confirmed the self-assembly of VCM/TS into NPs. The size, 
surface charge and drug loading of the SADDs was ˂100 nm, -27 mV and 68 %, respectively. 
The SADDs were non-haemolytic and biosafe. A sustained release of VCM from SADDs 
was noted, with 52.2 % release after 48 hr. The in vitro antibacterial test showed a two-fold 
decrease in MIC against SA and MRSA, and a significantly higher reduction in MRSA 
biofilms compared to bare VCM. Further, in silico studies confirmed strong and stable 
binding of TS to MRSA efflux pumps. The in vivo study using mice skin infection models 
showed a 9.5-fold reduction in bacterial load after treatment with SADDs, in comparison 
with bare VCM. These findings affirmed that VCM/TS NPs as a promising novel nano-
delivery for treating bacterial infections. 
Keywords: Self-assembled drug delivery system, D-α-tocopherol succinate, antibacterial, 
antimicrobial resistance, Vancomycin, Methicillin resistance Staphylococcus aureus, efflux 
pumps . 
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1- Introduction 
The discovery and development of antibiotics has increased life expectancy and improved the 
quality of life over the last 75 years. However, improper use and sub-optimal delivery of 
antibiotics via conventional dosage forms have contributed to the development of antibiotic 
resistance [125]. The multidrug bacterial resistance explosion has led to the current serious 
challenges with the treatment of infectious diseases; thus new therapeutic approaches to 
combat multi-drug resistant pathogens are in high demand [126]. 
Innovative strategies are needed to combat antibacterial resistance. Nano-delivery systems 
and novel preparations that form chemical bonds or physical encapsulation of the drug can 
target drugs to infectious sites, decrease the exposure of healthy tissues and provide 
controlled drug release. They are, therefore, able to improve efficacy, and decrease doses and 
frequency of administration; hence improving patient compliance and acting as a potential 
tool to solve the problem of antibiotic resistance [127, 128]. Despite the huge array of nano-
delivery systems and biomaterials that have been developed for drug delivery, combating 
bacterial resistance through these delivery systems is still challenging. The toxic and 
inflammatory effects of the nontherapeutic contents of drug delivery systems (DDS) and their 
metabolites are inherent drawbacks of DDS, apart from low drug loading and premature burst 
release prior to reaching the target site [129-131]. Innovative strategies to improve the drug 
loading and reduce nontherapeutic contents of DDS have been developed recently by 
researchers, where the drug was coupled, via cleavable bonds, with an amphiphilic system to 
form prodrugs [132-135]. 
Previously, various research groups have developed amphiphilic drug-drug conjugates, in 
which the drug forms the building blocks of the delivery system, resulting in self-delivery 
without the use of nontherapeutic carriers [83, 84]. Although the activity and drug loading are 
greatly enhanced, this strategy is still dependent on chemical modifications of the drug, 
which relies on the use of toxic reagents and organic solvents. An alternative to chemical 
modification is supramolecular chemistry, currently the most popular subfield of chemistry, 
which focuses on producing complex structures assembled from molecular subunits through 
weak interactions, such as hydrophobic-hydrophilic bonds, hydrogen-bonding, metal-ligand 
co-ordination, π–π stacking and van der Waal‘s (vdW) forces [136]. These supramolecular 
complexes are identified by their unique structure and extraordinary functions [90], which 
make them useful in building advanced biomaterials [55, 56] that have been employed as 
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therapeutic and diagnostic agents, including the production of new antibacterial compounds 
[91]. Recently, a new strategy to build self-assembled drug delivery systems (SADDs), based 
on supramolecular interactions, has been proposed, showing enhanced therapeutic efficacy by 
producing nanoparticles (NPs) composed only from therapeutic molecules without any 
chemical bonds [85-88]. An ideal example of this type of SADD is tetracycline (TTC) NPs, 
prepared using the sonochemical method [87]. The TTC NPs were formed through 
supramolecular hydrogen bonds between TTC molecules and showed enhanced antimicrobial 
activity [87]. Liu and co-workers reported SADDs based on supramolecular interactions 
between doxorubicin and chlorine e6, via π-π stacking, electrostatic and hydrophobic 
interactions [137]. The NPs produced were carrier-free, had the ability to improve the 
accumulation of drugs at a tumor site, enhance drug efficacy with reduced side effects and 
inhibit recurrence of tumors. This strategy of SADDs, based on supramolecular interactions, 
is relatively novel. Most reports focus on anticancer research as opposed to drug delivery in 
antibiotic resistance. 
Vancomycin (VCM) is a glycopeptide antibiotic used as one of the last resort treatments for 
Methicillin-resistant Staphylococcus aureus (MRSA), which is a major source of nosocomial 
and community-acquired bacterial infections [92]. This bacteria has acquired resistance to 
many antibiotics, due to their inappropriate use, inactivation of the drug via hydrolysis or 
chemical modification, genetic mutation resulting in modification of the target of the drug, 
and decreased intracellular accumulation of the antibiotic because of increased cell wall 
thickness or over-expression of efflux pumps [93, 94]. Of these mechanisms, efflux pumps 
have been pointed out as major contributors of multi drug resistance in Gram-positive and -
negative bacteria, as these efflux pumps extrude a wide variety of toxic compounds, 
including antibiotics from bacterial cells  [95, 96]. In Staphylococcus aureus (SA), the 
predominant family of efflux pumps are Major Facilitator Super family (MFS) proteins, 
particularly NorA and NorB [138, 139]. Recently, Niranjana et al. reported the ability of a 
ferulic acid derivative to improve the antibacterial activity of ciprofloxacin against a NorA 
over-expressed strain of SA. They confirmed through in vitro and in vivo studies that this 
enhancement is due to the inhibition of the efflux effect of NorA [140]. In another study, 
silybin was shown to restore the sensitivity of antibiotics against MRSA by decreasing 
expression of NorA [141]. Based on these facts, any compound in delivery system that can 
show the ability to interact with and/or inhibit these efflux pumps and lower the minimum 
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inhibitory concentration (MIC) of the antibiotic, can be considered a promising therapeutic 
agent that will aid in restoring the effectiveness of existing antibiotics [97, 98].  
Vitamin E is a naturally occurring antioxidant that is lipid-soluble and has the ability to 
solubilize several drugs that are hydrophobic [100]. D-α-tocopherol succinate (TS) is an FDA 
approved derivative of α-tocopherol, which is the most biologically active and abundant 
vitamin E isoform. Due to the high lipid solubility of α-tocopherol, it is able to modify the 
permeability of bacterial cell membranes, causing damage in the essential elements and 
collapse of proton pumps, leading to enhanced permeability and intracellular accumulation of 
different substances, including antibiotics [101]. Recent studies tested the effect of α-
tocopherol as an efflux pump inhibitor [101, 102], and in addition to that, α-tocopherol in 
combination with antibiotics has been described to enhance the sensitivity of drug resistant 
bacteria to antibiotics [102-105]. These features of α-tocopherol highlight the usefulness of 
this compound for the development of innovative antibacterial-resistant preparations, 
demonstrating the potential of α-tocopherol and its derivatives against efflux pumps like 
NorA and Nor B. 
Herein, we therefore report a novel SADD, composed of TS as hydrophobic part and VCM as 
hydrophilic part (VCM/TS complex), that will self-assemble into nanoparticles; and explore 
its potential for enhancing antibacterial activity of VCM against SA and MRSA, as well as 
for the eradication of biofilms. In this strategy, the antibiotic drug serves as building blocks to 
create well-defined NPs. The methods employed in the synthesis of the system have the 
potential for upscaling, commercialization and regulatory approval as no new chemical 
entities (NCEs) were formed among the approved excipients employed to synthesize the 
amphiphile. This is the first SADD formulation with TS for any class of drug, and the first 
SADD formulation of VCM. Additionally, in this study we aimed to investigate the potential 
of TS to block the outer membrane channel of NorA and NorB and possibly prevent 
extrusion of antibiotics via molecular dynamics (MD) simulations by determining the stable 
binding of TS to NorA and NorB efflux pumps at a molecular level. 
2. Materials and Methods 
2.1 Materials 
D-α-tocopherol succinate was obtained from Sigma-Aldrich (USA). Vancomycin 
hydrochloride, acquired from Sinobright Import and Export Co., Ltd. (China), was converted 
to the VCM-free base, according to a previously reported method [142]. 3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Merck 
Chemicals (Germany). For cell culture, cells were purchased from Highveld Biologicals 
(Johannesburg, South Africa). Cell culture reagents were purchased from Whitehead 
Scientific (Johannesburg, South Africa). For bacterial cultures, Mueller-Hinton Broth 
(MHB), Nutrient Broth and Mueller-Hinton Agar (MHA) were purchased from Biolab (South 
Africa). SA (ATCC 25923) and MRSA (SA Rosenbach ATCC BAA 1683) were purchased 
from DLD Scientific (South Africa). Water was purified using a Milli-Q water purification 
system (Millipore corp., USA). For Fourier transform-infrared (FT-IR) spectroscopy, we used 
a Bruker Alpha-p spectrometer with a diamond ATR (Germany). All reagents and solvents 
used in this study were of analytical grade. 
2.2 Preparation of Nanoparticles 
The VCM/TS NPs were prepared using a solvent evaporation technique [143]. Briefly, 10 mg 
of VCM was initially dissolved in 10 ml of purified water (1 mg/ml), followed by the drop-
wise addition of 1 ml of methanol (under stirring) containing dissolved TS in different molar 
ratios to VCM (1:1, 1:2, 1:3 and 1:6). The solution was left for at least 24 hours, to ensure 
evaporation of all methanol. The VCM/TS NPs were ultimately formed and characterized. 
2.3 Characterization 
2.3.1 Size, Polydispersity Index (PDI), Zeta Potential (ZP) and Morphology  
The VCM/TS NPs were characterized for their average size, PDI and ZP using a dynamic light 
scattering method. Appropriate dilutions of the formula were made using PBS. Measurements were 
recorded at room temperature (25º C) using a Zetasizer Nano ZS90 (Malvern Instruments, UK) fitted 
with a 633 nm laser at 173° detection optics. All parameters were analyzed in triplicate. A High 
Resolution Transmission Electron Microscope (HRTEM, JEOL 2100) was used to study the 
morphological features of the NPs. 
2.3.2 Dilution Effect 
Dilution studies were implemented to establish the stability of the NPs at low concentrations 
[144]. The size and PDI of NPs diluted with PBS (for 0, 10, 100 and 1000 times), were 
measured using a Zetasizer. Furthermore, the colloidal stability of the NPs when diluted with 
cell culture medium was evaluated by measuring the change in the size after dilution [137]. 
2.3.3 Short-Term Physical Stability 
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Physical appearance, particle size and ZP parameters were monitored over one month at room 
temperature (RT) and at 4°C, for stability evaluation [47]. 
2.3.4 Entrapment Efficiency (EE) and Drug Loading (DL)  
An ultrafiltration technique [145] was used to calculate the free VCM concentration by 
measuring absorbance at 280.4 nm and applying the Lambert-Beer law, to allow for the 
determination of drug loading (DL) and encapsulation efficiency (EE) of the NPs, according 
to the following equation:   
EE % = (total drug - free drug)/total drug × 100 
DL % = (total drug - free drug)/total weight of NPs × 100 
2.3.5 Vancomycin and Tocopherol Succinate Complex Self-Assembly 
2.3.5.1 Molecular dynamics of VCM/TS NPs complex 
To study the self-assembly of the VCM/TS complex, the UCSF Chimera tool was used to 
initially bind VCM to three molecules of TS and, thereafter, used to randomly insert six 
complexes of VCM and TS. Molecular dynamic simulations represent a complete toolset that 
explore the atomic arrangement within molecules, thus offering new viewpoints on the 
structural landscape of molecular systems. The MD simulations were carried out using the 
PMEMD engine of the Amber software package [146]. The system was then minimized for 
2500 steps with strong constraint on VCM, and TS for 1000 steps (500 steepest descent 
followed by 500 steps of the conjugate gradient), followed by 1000 steps of full minimization 
Langevin thermostat, with a collision frequency of 1.0 ps
-1
 with harmonic restraint of 5 
kcal.mol
-1
 Å
-2
 on the solutes, applied during the gradual heating up of the systems to a 
temperature of 300 K in the canonical ensemble for 50 ps. This was followed by 50 ps of 
density equilibration in NPT ensemble and a final 500 ps equilibration at 300 K, 1 bar 
pressure and a coupling constant of 2 ps. MD production was carried out for 54 ns using 
classical MD with a time step of 2 fs, with the frame being recorded at every 500 steps of 
simulation. All the bond lengths involving hydrogen atoms were constrained using the 
SHAKE algorithm [147]. All the MD simulations were carried out using the GPU Amber 14 
software package [148]. 
2.3.5.2 Binding free energy 
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To determine the binding free energy (ΔGbind) of VCM to TS, molecular mechanics integrated 
with the Poisson-Boltzmann or generalized Born surface area continuum solvation 
(MM/PBSA and MM/GBSA) method was used [149]. 
The MD simulation produced a trajectory represented by 50,000 snapshots, which were 
averaged to generate ΔGbind. The binding affinities between TS and the efflux pumps may be 
defined as: 
(1) ΔGbind = Gcomplex − Greceptor − Gligand 
(2) ΔGbind = Egas + Gsol – TS 
(3) Egas = Eint + EvDW + Eele 
(4) Gsol = GGB + GSA   
(5) GSA = γSASA 
where: 
Eele  Electrostatic potential energy from Coulomb forces 
Egas   Gas-phase energy (based on FF14SB force field terms) 
Eint  Internal energy 
EvdW  van der Waals energy 
Gsol  Solvation free energy 
GGB  Polar solvation energy 
GSA  non-polar solvation energy 
S  Total entropy of solute 
SASA  Solvent accessible surface area (water probe radius of 1.4 Å) 
T  Total entropy of temperature 
A per-residue energy decomposition was used to predict the contribution of every residue to 
the total ΔGbind at the ligand binding site, for significant residues of the pumps using the 
AMBER14 MM/GBSA method. 
2.3.6 In vitro biosafety 
2.3.6.1 Cytotoxicity and cell viability 
The MTT assay was applied in the determination of biosafety of VCM/TS [150] on Michigan 
Cancer Foundation-7 (MCF-7) breast cancer, human embryonic kidney 293 (HEK 293) and 
adenocarcinoma alveolar basal epithelial (A549). Cells were seeded at a concentration of 2.5 
x 10
3 
cells/well
 
into a 96-well plate containing 100 µl DMEM (HEK, MCF-7)/EMEM 
(A549), 10 % fetal bovine serum (FBS), 1 % pen-strep-fungizone and 1 % L-glutamine and 
incubated for 24 hr at 37 °C in a CO2 humidified incubator. Thereafter, different 
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concentrations of VCM/TS (20, 40, 60, 80 and 100 μg/ml) were added and incubated for a 
further 24 hr. Following the 24 hr incubation period, media were substituted with 100 μl of 
MTT solution (5 mg/ml in PBS) per well and incubated for 4 hr. The supernatant was then 
aspirated, and formazan crystals were solubilized using 100 μl of dimethyl sulfoxide. A 
microplate spectrophotometer (spectrostar nano, Germany) read absorbances at 540 nm 
(proportional to the number of live cells). The following equation was used to calculate the 
percentage cell viability: 
                 (
                     
                       
)        
2.3.6.2 Haemolysis  
A previously described method was used for the determination of percentage haemolysis 
[58]. Briefly, freshly collected sheep‘s blood was washed three times with autoclaved 
phosphate buffer saline (PBS, pH 7.4) by centrifugation at 2800 rpm for 5 min. VCM/TS NPs 
were diluted with PBS to a concentration ranging from 0.05 to 0.5 mg/ml for each sample. 
The red blood cell (RBC) suspension (0.2 ml) was added to 1.8 ml of each sample and left for 
incubation at 37 ⁰ C for 30 min. Thereafter the samples were centrifuged at 3000 rpm for 10 
min. Spectrophotometric readings of the supernatant of each sample at different 
concentrations were taken for the determination of haemoglobin release. To obtain 0 % and 
100 % haemolysis, 0.2 ml of RBC suspension was added to 1.8 ml PBS and distilled water, 
respectively. The degree of haemolysis was calculated using the following equation: 
             (
ABS ABS0
ABS100 ABS0
)       
where ABS100 and ABS0 are the absorbances of the solution at 100% and 0% haemolysis, 
respectively. 
2.3.7 Structural Changes 
Fourier transform-infrared spectroscopy was performed to determine the structural change in 
VCM and TS before and after self-assembly into NPs. 
2.3.8 Thermal Profiles  
The thermal profiles of the TS, VCM, lyophilized and physical mixture VCM/TS were 
ascertained using differential scanning calorimetry (DSC) (Shimadzu DSC-60, Japan) [151]. 
Briefly, an aluminium pan was loaded with samples (2 mg) and sealed using a crimper, 
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followed by heating under nitrogen flow, at a constant rate of 10 °C/min to 300 °C. For 
reference purposes, an empty pan was used. 
2.3.9 In Vitro Drug Release and Release Kinetics 
The sustain-release property of the VCM/TS NPs was confirmed using the dialysis method. 
Into dialysis bags, 2 ml of VCM/TS NPs solution containing 1mg/ml of VCM was loaded 
(cut-off: 14,000 Da) and 2 ml of bare VCM solution was used as a control. Thereafter, the 
loaded dialysis bags were immersed in 40 ml PBS (pH 7.4), at 37 °C, in a shaking incubator 
(100 rpm). After each interval time, 3 ml of PBS were withdrawn, and immediately replaced 
with fresh PBS. The experiment was repeated in triplicate. The released VCM was 
determined using a UV-spectrophotometer by measuring the absorbance at 280.4 nm. The 
release kinetics of VCM from the VCM/TS NPs was studied using different mathematical 
models: first order, Higuchi, Weibull and Korsmeyer-Peppas. To find the best fit model, the 
root means square error (RMSE) and correlation coefficient (R
2
) were determined, while the 
Korsmeyer-Peppas model was used to determine the release mechanism by calculating the 
value of the release exponent (n). The DDSolver software program was used for calculations 
[152].   
2.4 Antibacterial Efficacy 
2.4.1 In Vitro Antibacterial Activity 
The broth microdilution technique was used to determine the MIC values of VCM/TS NPs 
against SA and MRSA [153]. Briefly, an overnight culture in nutrient broth at 37 °C of SA 
and MRSA, in a shaker incubator, was diluted to 0.5 McFarland standard, using a DEN-1B 
McFarland densitometer (Latvia). In a 96-well plate, a specific volume of MHB was added, 
followed by the addition of an equal volume of bare VCM (positive control), TS solution in 
1% DMSO (negative control), and VCM/TS NPs in the first well; and then serially diluted. 
Then SA and MRSA were further diluted to 5 × 10
5
 colony-forming units per ml (CFU/ml), 
and added to the 96-well plate containing the serially diluted samples and MHB [154]. The 
experiments were carried out in triplicate. The broth mixture was incubated for 24 hr in a 
shaking incubator at 37 °C, then spotted on MHA plates, and incubated for 24 hr at 37 °C to 
observe the MIC values. 
2.4.2 In Silico Analysis of Tocopherol Succinate Binding to Efflux Pumps 
To understand the dynamics and binding interactions of the TS/NorA and TS/NorB systems 
at a molecular level, homology models of NorA and NorB were created to further elucidate 
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the binding pockets, which enabled the determination of binding energies and molecular 
forces that contribute to binding using molecular docking, MD simulation, binding-free 
energy calculations, per-residue energy decomposition analyses and post-dynamic analyses. 
2.4.2.1 Homology modelling and binding site determination of NorA and NorB  
Computer-aided drug design requires crystal structures of biomolecules to analyze molecular 
dynamics and inter/intramolecular interactions. Due to the lack of available crystal structures 
of NorA and NorB efflux pumps, we undertook homology modelling as a tool to develop 
models that could be used to understand the binding interactions between TS with NorA and 
NorB, respectively. To construct the models, the amino acid sequences for NorA and NorB 
from MRSA were accessed from UniProt (accession numbers P0A0J6 and Q8NWQ5, 
respectively) [155]. Thereafter, the predictive 3D structures were generated using the SWISS-
MODEL server (Figure S1 and S2) [156]. MolProbity was used to generate a Ramachandran 
Plot to assess and validate modified bond angles and torsional strain (Figure S3) [157]. 
Results revealed that for the NorA and NorB models, 94.35 % and 89.09 % of the respective 
protein's amino acid residues were in favoured regions. This left 4 and 14 outliers, 
respectively, none of which constituted the protein‘s active site.  
The MetaPocket server [158] was used to predict potential binding pockets on the surfaces of 
NorA and NorB models. The most hydrophobic binding pockets (within the channel of the 
efflux pumps) were then chosen for docking.  
2.4.2.2 Ligand acquisition and preparation 
The 3D structures of TS and VCM were acquired from PubChem [159] and thereafter 
subjected to optimization using Avogadro [160]. The ligands were prepared for molecular 
docking via Chimera software [161].  
2.4.2.3 Binding Affinity 
Molecular docking is well-known technique in drug development [102]. To predict the 
conformation and binding affinity of TS to NorA and NorB, molecular docking was applied 
herein to determine the binding mode and binding affinities of TS to NorA and NorB, 
respectively. The molecular docking software employed herein comprised UCSF Chimera, 
AutoDock MGL tools [162], AutoDockVina [163] and Raccoon [164], with default docking 
parameters. For docking preparation of each compound, hydrogen atoms and Gasteiger 
charges were added. In this study, two systems were docked: TS to NorA; and TS to NorB. 
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The docking poses with the highest binding affinity (kcal.mol
-1
) for each complex were then 
subjected to MD simulations. 
2.4.2.4 Molecular dynamics 
To determine the physical atomic motions that occur within the TS/NorA and TS/NorB 
systems, molecular dynamic simulations were performed on bound and unbound NorA and 
NorB systems. The MD simulations TS bound to NorA, TS bound to NorB and unbound 
NorA and NorB systems were performed using the PMEMD engine of the Amber software 
package [146]. Atomic partial charges were generated via ANTECHAMBER within the 
general Amber Force Field commands. The AMBER 14 Leap module immersed each system 
completely within a water box (10 Å TIP3P). For neutralization, Na
+
 or Cl
−
 counter-ions 
were added. An initial 2500 step minimization was performed, with a restraint potential of 
500 kcal/mol. Thereafter, a 1000-step full minimization was performed with no restraints. All 
systems were gradually heated to 300 K for 50 ps, such that each system provided a fixed 
number of atoms and volume. The solutes of the systems were subjected to a potential 
harmonic restraint of 10 kcal.mol
-1
Å
-2
. Thereafter, an equilibration step of 500 ps was 
conducted. An isobaric-isothermal ensemble (NPT) was imitated throughout the simulation 
(1 bar system pressure, constant number of atoms). The total simulation time of 100 ns for 
each system was performed, with the SHAKE algorithm to constrict hydrogen bonds, and a 
Langevin thermostat with collision frequency of 1 ps
-1
. 
2.4.2.5 Binding free energy and binding site residue identification 
To determine the ΔGbind of TS to NorA and NorB respectively, MM/GBSA was performed as 
mentioned in section 2.2.2. Thereafter, further analyses were carried out on the TS-NorA and 
TS-NorB complexes. 
2.4.2.6 Post-dynamic analyses 
The root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF) and 
thermodynamic energy of each system were then investigated to further understand the 
stability and energy contributions of the systems. All system co-ordinates were recorded in 1 
ps intervals and the trajectories analyzed via the AMBER 14 CPPTRAJ module [165].  
2.4.3 Reduction of MRSA Biofilm 
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Fluorescence microscopy was used to determine the potential of the VCM/TS NPS for  
eradication of MRSA biofilms [166]. MRSA biofilm was grown and treated with bare VCM 
and VCM/TS NPs following a previously published protocol by our group [47]. Briefly, 
biofilm was grown on cover slips. After formation of mature biofilm, the cover slips were 
washed and stained with Syto9 and propidium iodide (PI) dyes. Following 30 min. of 
incubation (dark), live (stained green) and dead cells (stained red) were detected using 
fluorescent optical microscopy (Nikon Eclipse 80i FM Japan). Three coverslips were 
observed for each sample. 
2.4.4 In Vivo Antibacterial Activity 
To further validate the therapeutic efficiency of VCM/TS NPs in depth, in vivo antibacterial 
activity of VCM/TS NPS was studied, using a MRSA skin infection model on BALB/c mice. 
The Animal Research Ethics Committee (AREC), University of KwaZulu-Natal (UKZN) has 
approved the protocol used for this study (Approval number: AREC/104/015PD) [167]. 
Compassionate care and treatment of the animals followed the regulations of the South 
African National Standard 10386:2008 and AREC of UKZN. BALB/c male mice weighing 
18 - 20 g, were obtained from the Biomedical Research Unit, UKZN. Mice back skin hairs 
were removed 24 hr preceding the experiment and 70 % ethanol was used to disinfect the 
intact, exposed skin. The following day, the mice were injected intradermally with 50 µl of 
MRSA (1.5 x 10
8
 CFU/ml) in saline. The mice were then divided into three groups: 
treatment, positive control and negative control groups (n = 4). Half an hour subsequent to 
infection, 50 µl of VCM/TS NPs formulation, free VCM, and saline, were injected 
intradermally at the same site of infection in the treatment, positive control, and negative 
control groups, respectively. The mice were observed for 48 hr with normal 12 hr light and 
dark conditions at 19-23 ⁰ C, and 55 ± 10 % relative humidity, with adequate ventilation. The 
mice were euthanized after 48 hr with halothane and the infected area of the skin was 
homogenized in PBS of pH 7.4 (5 ml). Tissue homogenates were serially diluted in PBS (pH 
7.4), after which 20 µl was spotted on nutrient agar plates, incubated at 37 °C for 24 hr, and 
the CFU counted. The CFU/ml was calculated using the following equation: 
        
                                    
                           
 
3. Results and discussion 
3.1 Preparation and Characterization of VCM/TS NPs 
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3.1.1 Size, PDI, ZP and Morphology 
Spontaneous aggregation of amphiphiles that are formed with noncovalent interactions 
between hydrophilic and hydrophobic segments, through supramolecular complexation, are 
showing potential in drug delivery [151, 168, 169]. VCM/TS NPs were formulated in a 
similar way, since VCM is soluble in water and TS is hydrophobic. TS was dissolved in 
methanol and added to the VCM solution dropwise in H2O under stirring. The mixture was 
left for a minimum of 24 hr to ensure evaporation of all methanol. As a control test, TS 
dissolved in methanol was added to pure distilled water under stirring, after which methanol 
evaporated and TS precipitated, due to the hydrophobicity of TS with no nanoaggregates 
forming. Different molar ratios of VCM and TS were determined to produce NPs with the 
desirable size, PDI, ZP and loading capacity. The sizes of the formed NPs were less than 100 
nm in all VCM:TS ratios tested, except NPs obtained from the ratio of 1:6 (Table 1). 
Accumulation of bacterial components at the infection site causes enhanced vascular 
permeability which subsequently results in feasible passive targeting [170]. Moreover, 
dysfunctional lymphatic drainage has also been reported in bacterial infection, which 
potentially promotes nanoparticle accumulation at the sites of infection [171]. The smaller 
sizes displayed by VCM/TS NPs could lead to enhanced permeability and retention effect 
when administered intravenously [34, 172]. The surface charge of NPs was approximately -
27 ± 1.3 mV. Previous studies showed that negatively charged NPs demonstration slow or 
reduced opsonization via the reticular endothelial system, which enhanced blood circulation 
time [109, 173-175]. The EE % increased with higher ratios of TS, as the highest EE% was 
observed with the ratio of 1:6 where it reached 75. 0 ± 3.5 %. In general, covalent linkage of 
drugs to carriers to form prodrugs is the most common strategy to get high drug loading [83, 
84]. Here we are utilizing the drug as the building block of the delivery system, which 
significantly reduces the use of carrier material. Furthermore, the drug loading capacity 
exceeds 70 %, indicating the potential of VCM/TS NPs as a novel SADDs. Therefore, the 
ratio of 1:3 was preferred because the size was less than 100 nm; more importantly the EE% 
for the selected ratio was higher than the smaller ratios; 1:1 and 1:2. Although the ratio of 1:6 
had higher EE%, the size of the formulated NPs were however more than 100 nm and the 
DL% was less than that for 1:3. A successful nanodelivery system should have a high drug 
loading capacity, thereby reducing the quantity of matrix materials for administration [176]. 
In addition, the PDI and ZP for the selected ratio were almost similar to the other ratio, hence, 
ratio of 1:3 was selected for further investigations [137, 177, 178]. HRTEM images showed 
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the selected formula of VCM/TS NPs to be solid spherical shapes (Figure 1), with the size 
almost similar to that measured using the DLS technique. The shape of the NPs is similar to 
other SADDs formulated via co-assembly of chlorine e6 and doxorubicin reported by Zhang 
et al. [137].  
Table 1: Size, PDI, ZP, EE % and DL % for the different molar ratios of TS used in 
formulation with VCM. The values are expressed as mean ± SD, (n=3). 
VCM:TS Size (nm) PDI Zeta (mV) EE% DL% 
1 to 1 69.14 ± 0.58 0.170 ± 0.003 -24 ± 0.12 45.5 ± 2.12 33.78 ± 2.12 
1 to 2 62.05 ± 0.47 0.201 ± 0.008 -28 ± 0.01 65.0 ± 3.4 38.37 ± 3.40 
1 to 3 85.15 ± 0.25 0.131 ± 0.017 -27 ± 1.30 68.8 ± 2.8 33.71 ± 2.80 
1 to 6 110.3 ± 0.65 0.114 ± 0.017 -32 ± 1.50 75.0 ± 3.5 24.34 ± 3.50 
 
 
Figure 1: Morphology of VCM/TS NPs from HRTEM and histogram for sample 
measurement showing size distribution measured via DLS. 
3.1.2 Dilution Effect 
Most colloidal formulations when administered to the systemic circulation undergo 
considerable changes [179]. Dilution studies were carried out to establish the stability of the 
NPs at low concentrations [144]. After dilutions up to 10 µg/ml (100 times) of the system 
(Table S1), there were no differences in size or PDI of the NPs. This indicated that, on 
injection in the body, the nano particles might not breakdown due to blood dilution, thereby 
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avoiding dose dumping. These results indicated the potential for administration of NPs 
without causing dose dumping due to systemic dilution. 
The surface adsorption of macromolecules, such as protein and lipids, onto the surface of NPs 
could lead to aggregation and colloidal destabilization when introduced into media or 
biological fluid [180]. The stability of the assembled NPs was tested when dispersed in 
DMEM supplemented with 10 % FBS, which indicated a slight increase in size by a shift in 
the distribution curve (Figure 2 A); and no extra peak was observed which could result from 
aggregation. This result showed that the system retained acceptable colloidal stability in the 
cell culture medium [137, 180, 181], as well as the aqueous medium. 
3.1.3 Short-Term Physical Stability 
Preliminary physical stability studies were carried out at RT and 4 °C, over one month to 
determine the impact of storage conditions on the VCM/TS NPs. Figures 2 B and C show no 
significant deviations in size and ZP, respectively, when the samples were stored at RT over 
one month. Generally, an absolute ZP value ≥ 20 mV, could prevent particle aggregation 
upon storage [182-184], due to the repulsion forces caused by the surface charge, which can 
overcome attracting vdW forces between particles. This result is in accordance with other 
reports for SADDs [137, 185], and indicate acceptable stability of the VCM/TS NPs in the 
aqueous phase at both RT and 4 °C storage condition. Long-term physical and chemical 
stability studies using international council of harmonization (ICH) conditions to assess the 
physical and chemical stability of the system must be undertaken on future drugs 
encapsulated in this system to confirm the shelf life. 
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Figure 2 A: Effect of DMEM containing 10 % FBS on particle size distribution measured by 
intensity for VCM/TS NPs. Figure B and C: Effect of storage time at RT over one month on 
size and charge, respectively. 
3.1.4 Molecular Dynamics of Self-Assembly of Vancomycin and Tocopherol Succinate  
Molecular visualization of interactions between VCM and TS (Figure 3) showed the spatial 
arrangement of the two molecules and the different type of bonds that cause them to interact. 
The total binding free energy was evaluated to gain an enhanced perspective of the binding 
energetics of the VCM and TS complex. The MM/GBSA package in AMBER was utilized to 
calculate the binding free energies by obtaining snapshots from the trajectories of the 
simulations. 
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Figure 3: Molecular visualization of interaction between VCM and three TS molecules TS 1, 
TS 2 and TS 3.  
Table 2: The binding energies (kcal/mol) for the VCM/TS computed from MD trajectories 
Energy Components (kcal/mol) 
Complex ΔEvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
VCM/TS1+ 
TS2+TS3 
-56.83 ± 0.81 -15.48 ± 0.56 -72.32 ± 1.07 29.92 ± 0.64 -42.40 ± 0.63 
VCM/TS1 -18.71 ± 0.34 -3.75 ± 0.41 -22.46 ± 0.56 7.63 ± 0.39 -14.82 ± 0.28 
VCM/TS2 -29.66 ± 0.56 -3.93 ± 0.35 -33.60 ± 0.78 8.83 ± 0.36 -24.77 ± 0.28 
VCM/TS3 -31.82 ± 0.43 -8.35 ± 0.50 -40.18 ± 0.60 15.51 ± 0.53 -24.66 ± 0.42 
 
As shown in Table 2, the contribution to the ΔG total from the vdW and electrostatic 
interactions was represented by ΔE vdW and ΔEelec. The polar and nonpolar solvation energy 
contributions to ΔG total were represented by ΔG gas and ΔG solvation, respectively. Binding 
between VCM and TS was mainly governed by the hydrophobic interaction, since ΔE gas 
  Pi-Pi T-shaped   Pi-Sulphur   Pi-Anion    Pi-Sigma   Conventional 
Hydrogen bond   Pi-Alkyl      Carbon      Amid-Pi Stacked      Attracting charge 
interaction     Salt bridge  
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was most favourable contributor, followed by ΔG vdW and ΔEelec. ΔG solvation was 
unfavourable for the binding; however, favourable ΔE gas and ΔG vdW lead to an overall 
favourable ΔG total. 
The last frame (100 ns) of the first simulation, in which VCM interacted with TS, was taken 
and replicated to make six complexes and 54 ns self-assembly simulations were performed. It 
was observed that these complexes began to assemble within a few ns after simulations 
(Figure 4). Simulation data revealed that, at ~15 ns, there were three dimers formed. At 32 ns 
two trimers were formed and a hexamer was formed at 54 ns. Overall, this data suggests that 
VCM/TS complexes  self-assemble in a way that has the hydrophilic VCM retained on 
solvent-accessible areas, while the hydrophobic TS was on the core, away from the solvent 
[186].  This result was similar to other simulation of complex amphiphile self-assembly 
studies [187], and also in line with the experimental results which showed these types of 
complexes are amphiphiles with self-assembling properties [185, 188]. The strong binding 
energies established between VCM and TS computationally correlate with the high 
experimental DL % and EE % reported in Table 1 [189]. 
 
Figure 4 a-d: Representative image of self-assembly simulation at different time intervals. 
3.1.5 In Vitro Biosafety 
3.1.5.1 Cytotoxicity and cell viability 
The cytotoxic effect of VCM/TS was determined via the in vitro MTT cytotoxicity assay. 
The MTT assay quantifies the number of healthy, living cells based on the metabolic 
reduction of yellow tetrazolium salt to crystalline formazan by living mammalian cells. The 
amount of formazan crystals produced is proportionate to viable cells present [150]. The 
results showed that cell viability ranged from 77.3 % to 108.5%, across all concentrations on 
all three tested cell lines (Figure 5). This is in accordance with the ISO norm for biomedical 
products (>70 % cell viability) [190]. In this study, no dose-dependent toxicity within the 
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concentration range to any of the three cell lines was reported. These results correlate with 
confirmed reports of biocompatibility and biosafety of TS [191], along with VCM as an FDA 
approved biosafe antibiotic, thus indicating the biosafety of the formulated VCM/TS NPs. 
 
Figure 5: MTT assay for evaluation of cytotoxicity of VCM/TS against A549, HEK 293 and 
MCF-7 cell lines. 
3.1.5.2 Haemolysis 
Blood compatibility is an important factor for all intravenously administered 
pharmaceuticals, to ensure there are non-haemolytic properties [192]. The unique 
physicochemical characteristics and the small size of the NPs may lead to interference with 
red blood cells (RBCs) more than the conventional pharmaceuticals, and hence early 
preclinical study to establish their biocompatibility with the blood component is necessary 
[193]. Red blood cells collected from sheep‘s blood was used to evaluate the haemolytic 
properties of VCM/TS NPs (Figure 6). Among the different concentrations used in the study 
(Table S2), the highest concentration of VCM/TS NPs (0.5 mg/ml) resulted in less than 1 % 
haemolysis of RBCs, signifying the non-haemolytic nature of VCM/TS NPs. 
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Figure 6: RBCs exposed to varying concentration of VCM/TS NPs and centrifuged. 
3.1.6 Structural Changes 
We further investigated whether the self-assembly of VCM with TS was accompanied by any 
structural or chemical modification. FT-IR spectra were acquired for VCM, TS and freeze-
dried VCM/TS NPs (Figure 7). The spectrum obtained for VCM/TS NPs showed all the 
characteristic peaks for the individual components, VCM and TS, and no new peaks were 
detected. Therefore, we may conclude that the hydrophobic interaction inducing the 
formation of VCM/TS NPs led to stabilization of the nanosystem without the formation of 
NCEs. This result is similar to other VCM NPs formulated via hydrogen-bond with 
poloxamer and sunflower oil through an ultrasonic emulsification method [57]; and also 
observed during the formation of penicillin nanospheres and tetracycline nanoparticles [87, 
194]. 
 
Figure 7: FT-IR spectrum of VCM, TS and VCM/TS NPs. 
3.1.7 Thermal profiles 
Differential scanning calorimetry is a useful technique to study the thermal behaviour of 
polyelectrolytes and biomaterials, which is correlated to their structure. DSC is highly 
utilized in drug delivery and formulation studies, since the endothermic and exothermic peak 
shifts are usually associated with interactions between drugs and the other components in the 
formula [195]. Thermal profiles for TS, VCM, a physical mixture of VCM/TS, and 
lyophilized VCM/TS NPs were recorded using DSC. Thermal profiles of both TS and VCM 
(Figure 8A and 8B) showed endothermic peaks at 83.12 °C and 126.21 °C, respectively, 
which probably represents the melting point of those two biomolecules. We observed the 
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same peaks in the physical mixture of VCM/TS, which indicate the absence of any type of 
interaction between the two molecules. Interestingly, the thermogram of lyophilized VCM/TS 
NPs did not show any peak for the individual components of the mixture, which suggests a 
change in the physicochemical properties of the mixture component and the development of 
interaction and the formation of new bonds between them and the amorphous state of 
VCM/TS NPs [196]. 
 
Figure 8 DSC thermogram of (A) TS, (B) VCM, (C) physical mixture of VCM/TS and (D) 
freeze-dried VCM/TS NPs. 
3.1.8 In Vitro Drug Release from the VCM/TS NPs  
An ideal nanodrug delivery system should have proper and stable nanosized particles and 
also be able to release the drug, because a system that cannot release the entrapped drug 
efficiently, or at all, is of no use [48]. The dialysis bag method was used to evaluate the 
releasing behaviour of VCM from the VCM/TS NPs, using bare VCM as the control. The 
result showed that the bare VCM was diffusing quickly through the dialysis bag membrane to 
the surrounding media until it was completely released after 8 hr (Figure 9), whilst the 
VCM/TS NPs release started quickly until it reached 45.6 % of the VCM in the system after 8 
hr. After 48 hr, VCM/TS NPs had a 52.2 % release of VCM. The release profile of the system 
was seen to be biphasic in nature. A similar biphasic profile has been reported before in the 
literature [134, 197, 198]. The quick first phase of VCM release from VCM/TS NPs was 
probably due to VCM molecules adsorbed on and/or encapsulated near the nano aggregates 
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surface, which resulted in the initial faster release via dissociation [199]. Another reason 
could be explained by the Noyes Whitney equation. At the initial stage, since there is a much 
high concentration gradient between the dialysis bag and the receiver compartment, it 
translates to higher release rates [200]. 
To understand the releases kinetics of the VCM/TS NPs, the cumulative release percentage 
curve was fitted using different release models (Table 3). A goodness-of-fit test was used as 
a limiting criteria for selecting the appropriate release model [201]. It was found that the 
Weibull equation is the best-fitting model to describe the release, based on it having the 
higher regression coefficient, R2 value (R
2
 = 0.933), compared to other models considered. In 
the Weibull model, the exponent parameter (β) value was found to provide a link with the 
drug release mechanism [202], which was found to be equal to 0.237 (Table 3), indicating 
Fickian diffusion as the release mechanism [202]. This result is also supported by the low (n) 
value (0.244) from the Korsmeyer-Peppas model, confirming the Fickian mechanism of 
release from the VCM/TS NPs, as the (n) value was less than 0.5 [142]. The Weibull model 
was used to describe the sustained release behaviour in many drug-loaded nanosystems [203-
205]. 
The good sustained release behaviour of VCM/TS NPs will be beneficial in exposing the 
bacteria to a continuous lethal dose and will facilitate the improvement of patient compliance 
by reducing the frequency of administration. 
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Figure 9: Cumulative release profile of VCM from VCM solution and VCM/TS NPs. 
Table 3: Drug release kinetics data for VCM/TS NPs. 
 
3.2 Antibacterial Activity 
3.2.1 In vitro antibacterial activity 
To evaluate the in vitro antibacterial activity of VCM/TS NPs against SA and MRSA, the 
broth dilution method was employed, and MICs were calculated for the bare VCM and NPs. 
Results (Table 4) indicated that the MICs for VCM and VCM/TS NPs against SA were 1.95 
µg/ml and 0.97 µg/ml, respectively; while for MRSA they were 3.9 µg/ml and 1.95 µg/ml, 
respectively. A TS solution in 1 % DMSO showed no activity at the concentration used. This 
two-fold reduction in MIC against SA and MRSA, with VCM transformed into an SADD 
Model Equation R
2
 Release exponent (n) β 
First Order 
Q = Q0 . e
kt
 0.013 - - 
Higuchi Q = k. t 
½
 0.503 - - 
Korsmeyer-Peppas Q = k . t
n
 0.756 0.244 - 
Weibull Q = 1 exp [-(t)a/b] 0.933 - 0.237 
 
69 
 
with TS, could be due to several features: a) Antibiotic transformation into nanosized 
particles confers novel modes of action due to the smaller size of the NPs, with unique 
properties, and enhances activity against bacteria, unlike those of free molecules and bulk 
materials [57]; b) There are several studies confirming the ability of TS to modify the 
permeability of bacterial cell membranes, causing damage in the essential elements and 
collapse of proton pumps due to the lipophilic nature of TS [101]. TS has been reported to 
have antimicrobial activity in higher concentrations, however, in the concentrations tested in 
our studies it did not show any antibacterial activity [103]. The binding effect of TS on NorA 
and NorB efflux pumps, and possible inhibition, may therefore have also led to the 
enhancement of the permeability of VCM through the bacterial cell membrane. The outcomes 
of this assay indicate the ability of VCM/TS NPs to release the bare VCM in an active form, 
resulting in enhanced antibacterial activity, compared to that of bare VCM. Having 
demonstrated superior in vitro antimicrobial activity of VCM/TS NPs over bare VCM, we 
then proceeded to supplement our studies with in silico analyses to identify and understand 
the stability of molecular interactions between TS with NorA and NorB, respectively, as a 
potential mechanism for enhancing the antibacterial activity of the VCM/TS NPs. 
Table 4: MIC values for bare VCM, VCM/TS NPs and TS. 
Material SA (MIC µg/ml) MRSA (MIC µg/ml) 
Time in hours 24 48 72 24 48 72 
Bare VCM 1.95 1.95 NA 3.9 3.9 NA 
VCM/TS NPs 0.97 0.97 0.97 1.95 1.95 1.95 
TS NA NA NA NA NA NA 
NA = No activity 
The values are expressed as mean, n = 3. 
3.2.2 In Silico Analysis of Tocopherol Succinate Binding to Efflux Pumps 
3.2.2.1 Predicted binding site determination 
To determine the sites on NorA and NorB to which TS can bind, MetaPocket [158] was used 
to predict possible hydrophobic binding pockets. Staphylococcus aureus NorA and NorB are 
chromosomally encoded efflux pumps whose overexpression can confer multidrug resistance 
of the bacteria to several antibiotics [206].  Understanding the active sites of NorA and NorB 
could offer perspectives on how to inhibit them. The active pockets of the NorA and NorB 
efflux pump proteins consist of hydrophobic amino acids. This hydrophilic nature may stem 
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from the location of the active site at the surface of the protein. Potential ligands at these 
active sites possess specific moieties and characteristics to be able to form a stable inhibitory 
complex. MetaPocket predicted hydrophobic binding pockets on the NorA and NorB 
proteins, and the two most hydrophobic pockets on each protein are highlighted in (Figure 
10). Herein, is presented for the first time the homology models of MRSA NorA and NorB 
and their potential binding sites to which TS can bind, to perform its antibacterial activity. 
 
Figure 10: The potential hydrophobic binding sites on NorA and NorB, identified by 
MetaPocket, with corresponding binding site amino acid residues. 
3.2.2.2 Binding affinity 
Molecular docking is one of the most useful in silico methods in drug development, as it 
predicts the mode of ligand binding to a target protein [207]. Molecular docking was applied 
in this study to determine the potential binding mode and binding affinities of TS to NorA 
and NorB, respectively (Figure 11). The conformation of TS that bound to NorA and NorB 
with highest affinities were -5.8 kcal/mol and -7.2 kcal/mol, respectively. This is a prediction 
of the affinities with which TS may bind to NorA and NorB in a bacterial cell wall. 
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Figure 11: Docking poses of TS bound to binding pockets of NorA (left) and NorB (right) 
with best binding affinities. 
3.2.2.3 Molecular dynamics 
Even though the scoring algorithm of molecular docking attempts to represent experimental 
binding, software predictions remain inconsistent. Therefore, MD simulations were applied to 
each docked system for 100 ns to validate binding using virtual conditions identical to 
experimental conditions, elaborating further on the structural dynamics of TS binding to both 
NorA and NorB. The unbound NorA and NorB proteins, as well as TS bound to NorA and 
NorB, were simulated.  
Throughout each simulation, TS remained stably bound to the proteins, without exiting the 
channel. The stability and convergence of each system were confirmed by analyzing the 
RMSD during the simulation. Both systems indicated stability – remained within a 2 Å range. 
Convergence in the TS-NorA and TS-NorB systems were reached after 45ns and 85ns, 
respectively (Figure S4). Increases in the radius of gyration of both systems upon binding 
(Figure S5) also confirmed the expansion of NorA and NorB to accommodate binding of TS. 
This, in turn, may block the efflux channel to prevent further efflux of compounds, including 
antibiotics, from the bacterial cell, which is seen as one of the main causes of resistance in 
gram-positive and gram-negative bacteria [95, 96]. 
Root-mean-square fluctuation (RMSF) revealed energy fluctuations of each amino acid 
residue of NorA and NorB when bound to TS, as in Figure 12, which shows a major shift in 
loop residues (175-200) and lower loop residues (193-259) of NorA and NorB, respectively. 
The fluctuations of these specific residues contribute the most to the adaption of NorA and 
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NorB upon TS binding. One can therefore postulate that these loops play major roles in 
allowing compounds, like TS, to enter the outer membrane channel of the pumps, thereby 
controlling the permeability of the bacterial cell wall.  
 
Figure 12: Time evolution of the simulation of TS bound to NorA (green) and NorB 
(maroon), and the root-mean-square fluctuation of the 100ns simulation of TS bound to NorA 
and NorB. 
3.2.2.4 Thermodynamic binding free energy and binding site residue identification 
To establish the forces and energies that contribute to the binding of TS to the efflux pumps 
situated in the bacterial cell wall, it is critical to calculate the binding free energy and per-
residue decomposition analysis. Figure 13 shows the amino acid residues of NorA and NorB 
that interact with TS after 100 ns of MD simulation. The ligand interaction diagram (Figure 
14A) reveals that Thr112, Met108, Thr313, Ile135, Gln50, Ile14, Asn339, Leu217, Phe15 and 
Ile18 of NorA form hydrophobic interactions with TS; while Glu221 forms a stable 
intermolecular hydrogen bond with TS. Figure 13F shows that residues Gln283, Ser45, 
Asn41, Val402, Gln20, Asn279, Gly397, Ser394, Trp16, Gly398, Leu267, Ala48, Phe15 and 
Trp132 of NorB form hydrophobic interactions with TS; while Ser136 and Lys391 form 
hydrogen bonds with TS. 
The energy components tables in Figures 13B and 13D provide a breakdown of energy 
contributions to binding, indicating that vdW forces and electrostatic energies play major 
roles in the binding of TS to NorA and NorB, respectively. The NorA and NorB proteins 
contribute more electrostatic energies toward binding (-26817.45 kcal/mol and -30572.07 
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kcal/mol, respectively) than vdW forces (-3036.37 kcal/mol and -3457.57 kcal/mol, 
respectively).  
The per-residue energy decomposition graphs in Figure 13 indicate that residues Phe15, 
Met108, Ile135, Thr335 and Asn339 of NorA are responsible for the high electrostatic energy 
contribution to binding shown in the table, while residues Ile135 and Arg309 provide most of 
the weak vdW forces involved in binding (Figure 13C). Figure 13E shows that residues 
Phe15, Trp16, and Asn279 contribute the most to the electrostatic binding of NorB to TS, 
while residues Trp132 and Ser136 bind with vdW forces. 
From this MD study, one can hypothesize that TS binds stably and may inhibit antibiotic 
expulsion by blocking the efflux pumps, which further supports the enhancement of the 
activity and reduction in the MIC values for VCM. Thus, using TS as an excipient in the 
delivery of antibiotics to MRSA is promising in the enhancement of antimicrobial activity. 
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Figure 13: Thermodynamic energy calculations and per-residue energy decomposition 
analysis of TS binding to NorA and NorB. A, F. Residue-ligand interaction diagram of TS 
forming hydrophobic interactions and hydrogens bond with NorA and NorB amino acid 
residues, respectively. B, D. Thermodynamic energy calculations of binding site residues of 
NorA and NorB, respectively. C, E. Per-residue energy decomposition analysis of TS bound 
to NorA and NorB, respectively. 
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3.2.3 Reduction of MRSA Biofilm 
Conventional antibiotics are not active against MRSA biofilm [208]. To determine the 
reduction effect of VCM/TS NPs on MRSA biofilm, untreated and treated biofilms were 
stained with Syto9 and PI and examined under a fluorescent microscope. For the untreated 
biofilms, the whole coverslip showed high intensity green colour when subjected to 
excitation at 488 nm, which is the range of Syto9; and since Syto9 is a cell permeant dye 
[209, 210], this is an indication of more living cells (Figure 14), compared to the dead cells 
(low intensity of red colour) that appeared when biofilms were stained and excited at the 
range of PI (Figure 14 ). Propidium iodide is a non-permeating dye and cannot penetrate an 
intact cell membrane [209]. Biofilms treated with VCM showed greater amounts of cells 
stained red compared to untreated biofilm, indicating more penetration of PI dye, due to 
ruptured and damaged cell walls caused by VCM treatment (Figure 14. B1 and B2). The 
biofilm disruption was more pronounced upon treatment with VCM/TS NPs, indicated by the 
high intensity of red fluorescence and complete lack of the green, as compared to the bare 
VCM (Figure 14. C1 and C2), confirming that there were many more dead cells than live 
ones, compared to the VCM treated biofilms. SA is one of the major biofilm-forming 
pathogens [211]. MRSA forms most of the adhered SA [212] and causes infections related to 
implanted medical devices. One of the features of biofilms is the extracellular polymeric 
substances, which play an important role in cell-surface or cell-cell attachment; and along 
with the intact biofilm structure, they act as a primary barrier for bacteria and prevent the 
entrance of the drug [213]. Bacteria embedded in biofilms are over 1000 times more resistant 
to antibiotics and the host immune system than those in culture [57]. The level of biofilm 
reduction caused by VCM/NPs indicates its superiority in eradication of MRSA biofilm 
compared to the bare VCM solution. This could be attributed to the fact that the nanoform of 
antibiotics usually leads to enhanced biofilm penetration, reaching the embedded bacteria 
more effectively than the drug solution [57]. It is possible that negatively charged VCM/TS 
NPs interact with the oppositely charged biofilm matrix electrostatically, and bind to the 
biofilm structure [214]. Additionally, TS has a significant anti-adhesive effect against SA 
biofilms [215], which could be due to interference with the initial event of biofilm formation. 
There could be a synergism between VCM and TS in planktonic bacteria via TS acting as an 
adjuvant to the antibiotic and efflux pump inhibitor, whilst the synergistic effect in biofilm 
inhibition could be via antiquorum sensing and enhanced transport of the drug across the 
biofilm protective barrier [103, 216]. Furthermore, there are reports of synergistic effects of 
efflux pump inhibitors and antibiotics against bacterial biofilms [217, 218]. There have been 
 
76 
 
detections of high levels of efflux pump (NorA and NorB) gene expression in biofilms. 
However, their influence on biofilm formation in MRSA is still largely unknown [219]. The 
frequent use of materials foreign to the body, such as contact lenses, prostheses and catheters 
highlights the necessity for, and enormous value of, a simple and effective system to treat 
biofilm-associated infections. 
 
Figure 14: Images from fluorescence microscopy for MRSA biofilms represent the untreated 
(A1 and A2), VCM-treated (B1 and B2) and VCM/TS NPs-treated (C1 and C2) biofilm. Live 
cells are stained with green and dead cells in red. 
3.2.4 In Vivo Antibacterial Activity 
For further evaluation of the antibacterial activity of VCM/TS NPs, a skin infection model 
was used. Local intradermal MRSA injections were delivered between the epidermal and the 
subcutaneous layer of the skin. Skin was then harvested around the injection site and 
homogenized and the number of colony-forming units (CFUs) were quantified for each 
treatment group and represented as log10 (Figure 15). One-way ANOVA analysis between all 
the treatment groups revealed that there was a statistically significant reduction (p < 0.0001) 
in bacterial load of the skin. The mean bacterial loads (log10 CFU) recovered from the 
untreated and bare VCM groups were 5.52 ± 0.01 (338,000 CFU/ml) and 4.40 ± 0.05 
(25,333.33 CFU/ml), respectively. These findings demonstrated that bare VCM had a 13.34-
fold reduction in bacterial load, when compared to the untreated group (p = 0.0007). In the 
VCM/TS NP treated groups, the bacterial load was 2.4 ± 0.17 log10 CFU/ml (2,666.667 
CFU/ml), which was 126-fold lower when compared to the untreated group (p < 0.0008). 
Furthermore, there was a 9.5-fold reduction in bacterial load after treatment with VCM/TS 
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NPs, compared to the bare VCM (p = 0.0077). This improvement in in vivo results compared 
to in vitro results for VCM/TS NPs could be due to enhanced penetration and retention of the 
nanosystem compared to the bare drug. Also, it could be due to enhanced drug release from 
the system in the in vivo conditions compared to the agar plate in the in vitro antibacterial 
study. A similar trend for superior in vivo results compared to in vitro results for nanodelivery 
systems have been reported [220]. These in vivo results demonstrated VCM/TS NPs as an 
effective drug delivery system for VCM. 
 
Figure 15: Evaluation of MRSA burden post 48 hr treatment. **denotes significant difference 
for VCM/TS NPs versus bare VCM. ***denotes significant difference between untreated 
versus bare VCM and also denotes a significant difference between untreated and VCM/TS 
NPs. Data are represented as means ± SD (n = 3). 
4. Conclusion 
In this study we described a method for the synthesis of a novel SADD comprising 
hydrophobic TS and hydrophilic VCM that self-assembled into NPs for delivery of VCM 
against SA and MRSA infections. The VCM/TS NPs self-assembly and stability were confirmed 
using MD simulation. The VCM/TS NP had a suitable size, surface charge and morphology for 
targeted antibiotic therapy. The NPs displayed an EE % of >60 % for VCM, which correlated with the 
strong binding established through MD. In vitro cell toxicity and haemolysis studies confirmed the 
biosafety of the system. The system showed a sustained release profile of VCM, which was ascribed 
to its enhanced and prolonged in vitro antibacterial effect when compared to bare VCM. Further, in 
silico studies showed the potential of TS to stably interact with MRSA NorA and NorB efflux 
pumps at a molecular level, indicating its potential as a constituent in a delivery system to 
inhibit efflux pumps for enhanced antibacterial activity. In vivo studies also confirmed the 
superiority of the NPs over the bare VCM by showing a significant reduction in bacterial load. The 
method employed in the synthesis of this SADD system with enhanced antibacterial activity 
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has the potential for upscaling, commercialization and regulatory approval as no NCEs were 
formed among the approved excipients used to synthesize the amphiphile. These findings 
indicate that VCM/TS NPs is a novel nano-delivery system that can be applied to improve 
treatment of bacterial infections and to fight bacterial resistance. 
5. Acknowledgement 
The authors acknowledge the College of Health Sciences, University of KwaZulu-Natal 
(UKZN), and the UKZN Nanotechnology Platform, the National Research Foundation (NRF) 
of South Africa (Grant No. 106040) and the Medical Research Council (MRC) of South 
Africa for financial support. We also acknowledge the Microscopy and Microanalysis Unit 
(MMU) and the Department of Human Physiology at UKZN, for use of their facilities, as 
well as the Centre for High Performance Computing (CHPC), Cape Town, for 
supercomputing resources. 
6. Conflict of Interest 
The authors declare that there is no conflict of interest. 
5. References 
1. English, B.K. and A.H. Gaur, The use and abuse of antibiotics and the development of 
antibiotic resistance, in Hot Topics in Infection and Immunity in Children VI. 2010, Springer. 
p. 73-82. 
2. Matzov, D., A. Bashan, and A. Yonath, A bright future for antibiotics? Annual 
Review of Biochemistry, 2017. 86: p. 567-583. 
3. Kalhapure, R.S., et al., Nanoengineered drug delivery systems for enhancing 
antibiotic therapy. Journal of Pharmaceutical Sciences, 2015. 104(3): p. 872-905. 
4. Li, S., et al., Antibacterial hydrogels. Advanced science, 2018. 5(5): p. 1700527. 
5. Lin, J., et al., Antibacterial zinc oxide hybrid with gelatin coating. Materials Science 
and Engineering: C, 2017. 81: p. 321-326. 
6. Yu, D., et al., Antitumor activity of poly (ethylene glycol)–camptothecin conjugate: 
The inhibition of tumor growth in vivo. Journal of Controlled Release, 2005. 110(1): p. 90-
102. 
7. Knop, K., et al., Poly (ethylene glycol) in drug delivery: pros and cons as well as 
potential alternatives. Angewandte Chemie International Edition, 2010. 49(36): p. 6288-6308. 
8. Sapra, P., et al., Novel delivery of SN38 markedly inhibits tumor growth in 
xenografts, including a camptothecin-11–refractory model. Clinical Cancer Research, 2008. 
14(6): p. 1888-1896. 
 
79 
 
9. Feng, X., et al., Electrospun polymer micro/nanofibers as pharmaceutical repositories 
for healthcare. Journal of Controlled Release, 2019. 
10. Wang, J., et al., Tumor redox heterogeneity‐ responsive prodrug nanocapsules for 
cancer chemotherapy. Advanced Materials, 2013. 25(27): p. 3670-3676. 
11. Zhang, H., et al., Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: 
in vitro and in vivo studies. Journal of Controlled Release, 2013. 166(2): p. 147-158. 
12. Ding, J., et al., Electrospun polymer biomaterials. Progress in Polymer Science, 2019. 
90: p. 1-34. 
13. Huang, P., et al., Combination of small molecule prodrug and nanodrug delivery: 
amphiphilic drug–drug conjugate for cancer therapy. Journal of The American Chemical 
Society, 2014. 136(33): p. 11748-11756. 
14. Xie, S., et al., Design and synthesis of theranostic antibiotic nanodrugs that display 
enhanced antibacterial activity and luminescence. Proceedings of the National Academy of 
Sciences, 2017. 114(32): p. 8464-8469. 
15. Huang, H., et al., Facile modification of nanodiamonds with hyperbranched polymers 
based on supramolecular chemistry and their potential for drug delivery. Journal of colloid 
and interface science, 2018. 513: p. 198-204. 
16. Ganewatta, M.S. and C. Tang, Controlling macromolecular structures towards 
effective antimicrobial polymers. Polymer, 2015. 63: p. A1-A29. 
17. Lehn, J.-M., Supramolecular chemistry. Science, 1993. 260(5115): p. 1762-1764. 
18. Amabilino, D.B., D.K. Smith, and J.W. Steed, Supramolecular materials. Chemical 
Society Reviews, 2017. 46(9): p. 2404-2420. 
19. Webber, M.J., et al., Supramolecular biomaterials. Nature Materials, 2016. 15(1): p. 
13. 
20. Kulkarni, A., et al., Combining immune checkpoint inhibitors and kinase-inhibiting 
supramolecular therapeutics for enhanced anticancer efficacy. Acs Nano, 2016. 10(10): p. 
9227-9242. 
21. Shimanovich, U., et al., Tetracycline Nanoparticles as Antibacterial and Gene‐
Silencing Agents. Advanced Healthcare Materials, 2015. 4(5): p. 723-728. 
22. Semiramoth, N., et al., Self-assembled squalenoylated penicillin bioconjugates: an 
original approach for the treatment of intracellular infections. ACS Nano, 2012. 6(5): p. 
3820-3831. 
23. Zhao, R., et al., Carrier-free nanodrug by co-assembly of chemotherapeutic agent and 
photosensitizer for cancer imaging and chemo-photo combination therapy. Acta 
biomaterialia, 2018. 70: p. 197-210. 
24. Zhang, R., et al., Carrier-free, chemophotodynamic dual nanodrugs via self-assembly 
for synergistic antitumor therapy. ACS Applied Materials & Interfaces, 2016. 8(21): p. 
13262-13269. 
25. Binda, E., F. Marinelli, and G. Marcone, Old and new glycopeptide antibiotics: action 
and resistance. Antibiotics, 2014. 3(4): p. 572-594. 
 
80 
 
26. Slama, T.G., Gram-negative antibiotic resistance: there is a price to pay. Critical Care, 
2008. 12(4): p. S4. 
27. Blair, J.M., et al., Molecular mechanisms of antibiotic resistance. Nature Reviews 
Ricrobiology, 2015. 13(1): p. 42. 
28. Saiful, A.J., et al., Efflux genes and active efflux activity detection in Malaysian 
clinical isolates of methicillin‐ resistant Staphylococcus aureus (MRSA). Journal of Basic 
Microbiology, 2008. 48(4): p. 245-251. 
29. Sołoducho, J., et al., Recent Advances of Modern Protocol for CC Bonds–The Suzuki 
Cross-Coupling. Advances in Chemical Engineering and Science, 2013. 3(3A): p. 19-32. 
30. Markham, P.N. and A.A. Neyfakh, Efflux-mediated drug resistance in Gram-positive 
bacteria. Current Opinion in Microbiology, 2001. 4(5): p. 509-514. 
31. Sabatini, S., et al., Pyrazolo [4, 3-c][1, 2] benzothiazines 5, 5-dioxide: a promising 
new class of Staphylococcus aureus NorA efflux pump inhibitors. Journal of Medicinal 
Chemistry, 2012. 55(7): p. 3568-3572. 
32. Sundaramoorthy, N.S., et al., Ferulic acid derivative inhibits NorA efflux and in 
combination with ciprofloxacin curtails growth of MRSA in vitro and in vivo. Microbial 
Pathogenesis, 2018. 124: p. 54-62. 
33. Wang, D., et al., Inhibitory effects of silybin on the efflux pump of 
methicillin‑ resistant Staphylococcus aureus. Molecular Medicine Reports, 2018. 18(1): p. 
827-833. 
34. Van Bambeke, F. and V.J. Lee, Inhibitors of bacterial efflux pumps as adjuvants in 
antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Patents 
on Anti-infective Drug Discovery, 2006. 1(2): p. 157-175. 
35. Lomovskaya, O., et al., Identification and characterization of inhibitors of multidrug 
resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. 
Antimicrobial Agents and Chemotherapy, 2001. 45(1): p. 105-116. 
36. Nielsen, P., et al., The effect of α-tocopherol on the in vitro solubilisation of lipophilic 
drugs. International Journal of Pharmaceutics, 2001. 222(2): p. 217-224. 
37. Tintino, S.R., et al., Action of cholecalciferol and alpha-tocopherol on Staphylococcus 
aureus efflux pumps. EXCLI Journal, 2016. 15: p. 315. 
38. Abd El-Tawab, A.A., et al., Efflux Pump Inhibitors, Alpha-Tocopherol and Aspirin: 
Role in Campylobacter jejuni and Campylobacter coli Fluoroquinolone Resistance. Microbial 
Drug Resistance, 2018. 25: p. 203-211. 
39. Andrade, J.C., et al., Enhancement of the antibiotic activity of aminoglycosides by 
alpha-tocopherol and other cholesterol derivates. Biomedicine & Pharmacotherapy, 2014. 
68(8): p. 1065-1069. 
40. Tintino, S.R., et al., Vitamin K enhances the effect of antibiotics inhibiting the efflux 
pumps of Staphylococcus aureus strains. Medicinal Chemistry Research, 2018. 27(1): p. 261-
267. 
41. Du, Y., et al., Tocopherol polyethylene glycol succinate modified hollow silver 
nanoparticles for combating bacteria-resistance. Biomaterials Science, 2019. 
 
81 
 
42. Kalhapure, R.S., et al., Ion pairing with linoleic acid simultaneously enhances 
encapsulation efficiency and antibacterial activity of vancomycin in solid lipid nanoparticles. 
Colloids and Surfaces B: Biointerfaces, 2014. 117: p. 303-311. 
43. Rabani, E., et al., Drying-mediated self-assembly of nanoparticles. Nature, 2003. 
426(6964): p. 271. 
44. Zuo, H., et al., Crosslinking to enhance colloidal stability and redispersity of layered 
double hydroxide nanoparticles. Journal of Colloid and Interface Science, 2015. 459: p. 10-
16. 
45. Omolo, C.A., et al., A hybrid of mPEG-b-PCL and G1-PEA dendrimer for enhancing 
delivery of antibiotics. Journal of Controlled Release, 2018. 290(1): p. 112-128. 
46. Sonawane, S.J., et al., Ultra-small lipid-dendrimer hybrid nanoparticles as a promising 
strategy for antibiotic delivery: In vitro and in silico studies. International Journal of 
Pharmaceutics, 2016. 504(1–2): p. 1-10. 
47. Case, D., et al., AMBER 2018; 2018. University of California, San Francisco. 
48. Ryckaert, J.-P., G. Ciccotti, and H.J. Berendsen, Numerical integration of the 
cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. 
J. Comput. Phys., 1977. 23(3): p. 327-341. 
49. Case, D.A., et al., The Amber biomolecular simulation programs. Journal of 
Computational Chemistry, 2005. 26(16): p. 1668-1688. 
50. Devnarain, N. and M.E. Soliman, Molecular mechanism of resveratrol inhibition of 
Zika virus NS3 helicase: behind the scenes. Future Virology, 2019. 14(2): p. 73-84. 
51. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application 
to proliferation and cytotoxicity assays. Journal of Immunological Methods, 1983. 65(1-2): p. 
55-63. 
52. Salih, M., et al., Supramolecular Amphiphiles of Beta-Cyclodextrin and Oleylamine 
for enhancement of Vancomycin delivery. International Journal of Pharmaceutics, 2019: p. 
118881. 
53. Zhang, Y., et al., DDSolver: An Add-In Program for Modeling and Comparison of 
Drug Dissolution Profiles. The AAPS Journal, 2010. 12(3): p. 263-271. 
54. Jorgensen, J.H. and J.D. Turnidge, Susceptibility test methods: dilution and disk 
diffusion methods, in Manual of Clinical Microbiology, Eleventh Edition. 2015, American 
Society of Microbiology. p. 1253-1273. 
55. Jorgensen, H., Methods for dilution antimicrobial susceptibility tests for bacteria that 
grow aerobically. Approved standard. National Committee for Clinical Laboratory Standards 
Antimicrobial Susceptibility Testing, 1993: p. NCCLS M7-A3. 
56. Consortium, U., UniProt: a worldwide hub of protein knowledge. Nucleic Acids 
Research, 2018. 47(D1): p. D506-D515. 
57. Waterhouse, A., et al., SWISS-MODEL: homology modelling of protein structures 
and complexes. Nucleic Acids Research, 2018. 46(W1): p. W296-W303. 
58. Williams, C.J., et al., MolProbity: More and better reference data for improved all‐
atom structure validation. Protein Science, 2018. 27(1): p. 293-315. 
 
82 
 
59. Zhang, Z., et al., Identification of cavities on protein surface using multiple 
computational approaches for drug binding site prediction. Bioinformatics, 2011. 27(15): p. 
2083-2088. 
60. Kim, S., et al., PubChem substance and compound databases. Nucleic Acids 
Research, 2015. 44(D1): p. D1202-D1213. 
61. Rayan, B. and A. Rayan, Avogadro Program for Chemistry Education: To What 
Extent can Molecular Visualization and Three-dimensional Simulations Enhance Meaningful 
Chemistry Learning. World Journal of Chemical Education, 2017. 5(4): p. 136-141. 
62. Pettersen, E.F., et al., UCSF Chimera—a visualization system for exploratory 
research and analysis. Journal of Computational Chemistry, 2004. 25(13): p. 1605-1612. 
63. Sanner, M.F., The Python interpreter as a framework for integrating scientific 
computing software-components. Scripps Res. Inst., 2008. 26(1): p. 1-12. 
64. Trott, O. and A.J. Olson, AutoDock Vina: improving the speed and accuracy of 
docking with a new scoring function, efficient optimization, and multithreading. Journal of 
Computational Chemistry, 2010. 31(2): p. 455-461. 
65. Ramírez, D. and J. Caballero, Is it reliable to use common molecular docking methods 
for comparing the binding affinities of enantiomer pairs for their protein target? International 
Journal of Molecular Sciences, 2016. 17(4): p. 525. 
66. Roe, D.R. and T.E. Cheatham III, PTRAJ and CPPTRAJ: software for processing and 
analysis of molecular dynamics trajectory data. Journal of Chemical Theory and 
Computation, 2013. 9(7): p. 3084-3095. 
67. Berlutti, F., et al., Influence of sub-inhibitory antibiotics and flow condition on 
Staphylococcus aureus ATCC 6538 biofilm development and biofilm growth rate: BioTimer 
assay as a study model. The Journal of Antibiotics, 2014. 67(11): p. 763. 
68. Kugelberg, E., et al., Establishment of a superficial skin infection model in mice by 
using Staphylococcus aureus and Streptococcus pyogenes. Antimicrobial agents and 
chemotherapy, 2005. 49(8): p. 3435-3441. 
69. Hamman, J.H., Chitosan based polyelectrolyte complexes as potential carrier 
materials in drug delivery systems. Marine Drugs, 2010. 8(4): p. 1305-1322. 
70. Zarif, M., et al., Physicochemical characterization of vancomycin and its complexes 
with?-cyclodextrin. 2012. 
71. Lee, W.L. and W.C. Liles, Endothelial activation, dysfunction and permeability 
during severe infections. Current opinion in hematology, 2011. 18(3): p. 191-196. 
72. Gao, W., et al., Nanoparticle approaches against bacterial infections. Wiley 
Interdiscip. Rev. Nanomed. Nanobiotechnol., 2014. 6(6): p. 532-547. 
73. Zaidi, S., L. Misba, and A.U. Khan, Nano-therapeutics: a revolution in infection 
control in post antibiotic era. Nanomedicine: Nanotechnology, Biology and Medicine, 2017. 
13(7): p. 2281-2301. 
74. Yang, L., et al., Triclosan-based supramolecular hydrogels as nanoantibiotics for 
enhanced antibacterial activity. Journal of Controlled Release, 2020. 
 
83 
 
75. Zhu, M., et al., Physicochemical properties determine nanomaterial cellular uptake, 
transport, and fate. Accounts of Chemical Research, 2012. 46(3): p. 622-631. 
76. Owens III, D.E. and N.A. Peppas, Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 2006. 
307(1): p. 93-102. 
77. Moghimi, S.M. and H. Patel, Serum-mediated recognition of liposomes by phagocytic 
cells of the reticuloendothelial system–the concept of tissue specificity. Advanced Drug 
Delivery Reviews, 1998. 32(1-2): p. 45-60. 
78. Jahed, V., et al., NMR (1H, ROESY) spectroscopic and molecular modelling 
investigations of supramolecular complex of β-cyclodextrin and curcumin. Food chemistry, 
2014. 165: p. 241-246. 
79. Singh, R. and J.W. Lillard Jr, Nanoparticle-based targeted drug delivery. 
Experimental and molecular pathology, 2009. 86(3): p. 215-223. 
80. Zhao, Y., et al., Novel carrier-free nanoparticles composed of 7-ethyl-10-
hydroxycamptothecin and chlorin e6: Self-assembly mechanism investigation and in vitro/in 
vivo evaluation. Colloids and Surfaces B: Biointerfaces, 2020. 188: p. 110722. 
81. Nel, A.E., et al., Understanding biophysicochemical interactions at the nano–bio 
interface. Nature Materials, 2009. 8(7): p. 543. 
82. Moore, T.L., et al., Nanoparticle administration method in cell culture alters particle-
cell interaction. Scientific Reports, 2019. 9(1): p. 900. 
83. Kittler, S., et al., The influence of proteins on the dispersability and cell-biological 
activity of silver nanoparticles. Journal of Materials Chemistry, 2010. 20(3): p. 512-518. 
84. Bose, S., et al., Formulation optimization and topical delivery of quercetin from solid 
lipid based nanosystems. International Journal of Pharmaceutics, 2013. 441(1-2): p. 56-66. 
85. Katara, R., S. Sachdeva, and D.K. Majumdar, Design, characterization, and evaluation 
of aceclofenac-loaded Eudragit RS 100 nanoparticulate system for ocular delivery. 
Pharmaceutical development and technology, 2019. 24(3): p. 368-379. 
86. Katara, R., S. Sachdeva, and D.K. Majumdar, Enhancement of ocular efficacy of 
aceclofenac using biodegradable PLGA nanoparticles: formulation and characterization. 
Drug Delivery and Translational Research, 2017. 7(5): p. 632-641. 
87. Fan, L., et al., Carrier-free, pure nanodrug formed by the self-assembly of an 
anticancer drug for cancer immune therapy. Molecular Pharmaceutics, 2018. 15(6): p. 2466-
2478. 
88. Microbiology, E.C.f.A.S.T.o.t.E.S.o.C. and I. Diseases, Terminology relating to 
methods for the determination of susceptibility of bacteria to antimicrobial agents. Clinical 
Microbiology and Infection, 2000. 6(9): p. 503-508. 
89. Sikwal, D.R., et al., Polyelectrolyte complex of vancomycin as a nanoantibiotic: 
Preparation, in vitro and in silico studies. Materials Science and Engineering: C, 2016. 63: p. 
489-498. 
 
84 
 
90. Zhang, Z., et al., Construction of a supramolecular drug–drug delivery system for 
non-small-cell lung cancer therapy. ACS Applied Materials & Interfaces, 2017. 9(35): p. 
29505-29514. 
91. Gayathri, N.K., et al., Preparation, characterization, drug release and computational 
modelling studies of antibiotics loaded amorphous chitin nanoparticles. Carbohydr Polym, 
2017. 177: p. 67-76. 
92. Standard, I., Biological Evaluation of Medical Devices. Tests for in vitro 
Cytotoxicity. Switzerland, Geneva: ISO. TC, 2009. 194. 
93. Kogure, K., et al., Cytotoxicity of α-tocopheryl succinate, malonate and oxalate in 
normal and cancer cells in vitro and their anti-cancer effects on mouse melanoma in vivo. 
Journal of Nutritional Science and Vitaminology, 2005. 51(6): p. 392-397. 
94. Yalkowsky, S.H., J. Krzyzaniak, and G. Ward, Formulation‐ related problems 
associated with intravenous drug delivery. Journal of Pharmaceutical Sciences, 1998. 87(7): 
p. 787-796. 
95. Dobrovolskaia, M.A., et al., Method for analysis of nanoparticle hemolytic properties 
in vitro. Nano Lett., 2008. 8(8): p. 2180-2187. 
96. Fernandes, M.M., et al., Nanotransformation of vancomycin overcomes the intrinsic 
resistance of gram-negative bacteria. ACS Appl. Mater. Interfaces, 2017. 9(17): p. 15022-
15030. 
97. Fernandes, M.M., et al., Escherichia coli and Pseudomonas aeruginosa eradication by 
nano-penicillin G. Nanomedicine: Nanotechnology, Biology and Medicine, 2016. 12(7): p. 
2061-2069. 
98. Sarmento, B., et al., Characterization of insulin-loaded alginate nanoparticles 
produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydrate Polymers, 
2006. 66(1): p. 1-7. 
99. Saganowska, P. and M. Wesolowski, DSC as a screening tool for rapid co-crystal 
detection in binary mixtures of benzodiazepines with co-formers. Journal of Thermal 
Analysis and Calorimetry, 2018. 133(1): p. 785-795. 
100. Rizvi, S.A. and A.M. Saleh, Applications of nanoparticle systems in drug delivery 
technology. Saudi Pharmaceutical Journal, 2018. 26(1): p. 64-70. 
101. Liu, M., et al., Characterization and release of triptolide-loaded poly (D, L-lactic acid) 
nanoparticles. European Polymer Journal, 2005. 41(2): p. 375-382. 
102. Arriagada, F., et al., Development and characterization of florfenicol-loaded BSA 
nanoparticles as controlled release carrier. AAPS PharmSciTech, 2019. 20(5): p. 202. 
103. Zhu, D., et al., Folate-targeted polymersomes loaded with both paclitaxel and 
doxorubicin for the combination chemotherapy of hepatocellular carcinoma. Acta 
biomaterialia, 2017. 58: p. 399-412. 
104. Smith, B.T., Remington education: physical pharmacy. 2015: Pharmaceutical Press. 
105. Bamba, M., et al., Release mechanisms in gelforming sustained release preparations. 
International Journal of Pharmaceutics, 1979. 2(5-6): p. 307-315. 
 
85 
 
106. Papadopoulou, V., et al., On the use of the Weibull function for the discernment of 
drug release mechanisms. International Journal of Pharmaceutics, 2006. 309(1-2): p. 44-50. 
107. Zhang, H., F.-M. Zhang, and S.-J. Yan, Preparation, in vitro release, and 
pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles. 
International Journal of Nanomedicine, 2012. 7: p. 2901. 
108. Adibkia, K., et al., Piroxicam nanoparticles for ocular delivery: physicochemical 
characterization and implementation in endotoxin-induced uveitis. Journal of Drug Targeting, 
2007. 15(6): p. 407-416. 
109. Ji, J., et al., Preparation, characterization and in vitro release of chitosan nanoparticles 
loaded with gentamicin and salicylic acid. Carbohydrate Polymers, 2011. 85(4): p. 803-808. 
110. Costa, S.S., et al., Multidrug efflux pumps in Staphylococcus aureus: an update. The 
Open Microbiology Journal, 2013. 7: p. 59. 
111. Mukesh, B. and K. Rakesh, Molecular docking: a review. International Journal of 
Research in Ayurveda & Pharmacy, 2011. 2(6): p. 1746-1751. 
112. Kannappan, A., et al., Antibiofilm activity of Vetiveria zizanioides root extract 
against methicillin-resistant Staphylococcus aureus. Microbial Pathogenesis, 2017. 110: p. 
313-324. 
113. Mah, T.-F., et al., A genetic basis for Pseudomonas aeruginosa biofilm antibiotic 
resistance. Nature, 2003. 426(6964): p. 306. 
114. Fittipaldi, M., A. Nocker, and F. Codony, Progress in understanding preferential 
detection of live cells using viability dyes in combination with DNA amplification. Journal of 
Microbiological Methods, 2012. 91(2): p. 276-289. 
115. Archer, N.K., et al., Staphylococcus aureus biofilms: properties, regulation, and roles 
in human disease. Virulence, 2011. 2(5): p. 445-459. 
116. Gad, G.F.M., et al., Detection of icaA, icaD genes and biofilm production by 
Staphylococcus aureus and Staphylococcus epidermidis isolated from urinary tract 
catheterized patients. The Journal of Infection in Developing Countries, 2009. 3(05): p. 342-
351. 
117. Macia, M., E. Rojo-Molinero, and A. Oliver, Antimicrobial susceptibility testing in 
biofilm-growing bacteria. Clinical Microbiology and Infection, 2014. 20(10): p. 981-990. 
118. Ikuma, K., A.W. Decho, and B.L. Lau, When nanoparticles meet biofilms—
interactions guiding the environmental fate and accumulation of nanoparticles. Frontiers in 
Microbiology, 2015. 6: p. 591. 
119. Bidossi, A., et al., In vitro comparison between α-tocopheryl acetate and α-tocopheryl 
phosphate against bacteria responsible of prosthetic and joint infections. PloS One, 2017. 
12(7): p. e0182323. 
120. Gajdács, M. and G. Spengler, The role of drug repurposing in the development of 
novel antimicrobial drugs: Non-antibiotic pharmacological agents as quorum sensing-
inhibitors. Antibiotics, 2019. 8(4): p. 270. 
 
86 
 
121. Memariani, H., M. Memariani, and A. Ghasemian, An overview on anti-biofilm 
properties of quercetin against bacterial pathogens. World Journal of Microbiology and 
Biotechnology, 2019. 35(9): p. 143. 
122. Liu, Y., L. Yang, and S. Molin, Synergistic activities of an efflux pump inhibitor and 
iron chelators against Pseudomonas aeruginosa growth and biofilm formation. Antimicrobial 
agents and chemotherapy, 2010. 54(9): p. 3960-3963. 
123. Zimmermann, S., et al., Clinically approved drugs inhibit the Staphylococcus aureus 
multidrug NorA efflux pump and reduce biofilm formation. Frontiers in Microbiology, 2019. 
10: p. 2762. 
124. Jeong, Y.-I., et al., Ciprofloxacin-encapsulated poly (DL-lactide-co-glycolide) 
nanoparticles and its antibacterial activity. International journal of pharmaceutics, 2008. 
352(1-2): p. 317-323. 
 
87 
 
CHAPTER 4, EXPERIMENTAL PAPER 3 
5.1 Introduction  
This chapter addresses Aim 3, Objectives 1 – 6 and is a first-authored experimental article 
accepted in Journal of Biomolecular Structure & Dynamics (Impact Factor 3.22) an ISI 
international journal (manuscript ID: TBSD-2020-1529). This article highlights the 
synthesis of a novel polymeric conjugation of FA with a biodegradable polymer; PEG, 
the in vitro toxicity evaluation, molecular dynamics simulation of the self-assembly of 
NPs, characterization of its physical properties, binding check for FA, bilirubin and PEG-
FA molecules with HSA using MST, and in vitro antibacterial properties. 
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Abstract 
The global antimicrobial resistance crisis has prompted worldwide efforts to develop new and 
more efficient antimicrobial compounds, as well as to develop new drug delivery strategies 
and targeting mechanisms. This study aimed to synthesize a novel polyethylene glycol-
fusidic acid (PEG-FA) conjugate for self-assembly into nano-sized structures and explore its 
potential for simultaneously enhancing aqueous solubility and antibacterial activity of FA. In 
addition, the ability of PEG-FA to bind to HSA with lower affinity than FA is also 
investigated. Haemolysis and in vitro cytotoxicity studies confirmed superior biosafety of the 
novel PEG-FA compared to FA. The water solubility of FA after PEG conjugation was 
increased by 25-fold compared to the bare drug. PEG-FA nanoparticles displayed particle 
size, polydispersity index and zeta potential of 149.3 ± 0.21 nm, 0.267 ± 0.01 and 5.97 ± 1.03 
mV, respectively. Morphology studies using high resolution transmission electron 
microscope revealed a homogenous spherical shape of the PEG-FA nanoparticles. In silico 
studies showed that Van der Waals forces facilitated PEG-FA self-assembly. HSA binding 
studies showed that PEG-FA had very weak or no interaction with HSA using in silico 
molecular docking (-2.93 kcal/mol) and microscale thermophoresis (Kd = 14999 ± 1.36 µM), 
which may prevent bilirubin displacement. Conjugation with PEG did not inhibit the 
antibacterial activity of FA but rather enhanced it by 2.5-fold against Staphylococcus aureus 
and methicillin-resistant Staphylococcus aureus, compared to the bare FA. These results 
show that PEG-FA can simultaneously enhance solubility and antibacterial activity of FA, 
whilst also reducing binding of HSA to decrease its side effects. 
Keywords: Fusidic acid; Polyethylene glycol; Staphylococcus aureus; Methicillin-Resistant 
Staphylococcus aureus; Human serum albumin; Bilirubin; Microscale Thermophoresis  
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1. Introduction 
Infectious diseases caused by pathogenic microorganisms, such as bacteria, impose a 
significant threat to global health and remain a major contributor to premature mortality. 
Recent statistics showed an estimated 700,000 annual deaths worldwide [18], with the United 
States specifically showing 2.8 million severe illnesses cases and 35,000 annual deaths in 
2019 due to pathogenic resistant bacteria [221]. These numbers are significantly higher than 
the previous report from 2013. Factors such as high cost, lengthy process of development and 
regulatory approval of new drugs, and high attrition rates at final stages of testing, amongst 
others [35], have resulted in a 90% decline in the development and regulatory approval of 
new antibiotics [15]. Therefore, scientists are focusing on less time consuming and more 
cost-effective approaches to enhance the efficacy of old antibiotics through modification of 
their structures and reformulation into nanosystems [128, 222]. 
Nanotechnology is recognized as an effective strategy to deliver and improve the activity of 
different antibiotics, with some nano-drug delivery systems have already reached the market 
[33, 40, 41]. The most attractive feature of nanoparticles (NPs) as drug delivery vehicles are 
their ability to introduce a wide range of therapeutics, either attached to their large surface 
area or contained within the structure. This characteristic enhances the solubility of poorly 
soluble drugs, allowing for sustained and controlled drug release, improving cellular 
internalization, providing efficient delivery to the site of infection and preventing exposure of 
the drug to healthy cells [42, 43, 223]. Therefore, utilizing nanotechnology to fabricate a 
delivery system for old antibiotics, such as fusidic acid (FA), can potentiate their applications 
and protect the deterioration of the numbers of effective antibiotics available to treat resistant 
bacterial diseases. 
Fusidic acid, an antibiotic which belongs to the fusidane group, was first isolated from 
Fusidium coccineum fungus in 1962 [120]. Structurally, FA is a tetracyclic triterpenoid, with 
a ring system similar to steroid compounds, but has no corticosteroid effect. It is a slightly 
hygroscopic white powder, practically insoluble in water. FA is active against 
Staphylococcus aureus (S. aureus) and methicillin-resistant Staphylococcus aureus (MRSA) 
strains [121]. Due to the global crisis of antimicrobial resistance, there is an increasing 
research focus on FA, as it has a unique mechanism of action and lacks significant cross-
resistance to other classes of antibiotics [224-226]. A novel safe and effective dosing regimen 
for oral drug monotherapy for FA has been patented recently in the United States to fight 
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against MRSA [227]. Phase 2 clinical trials investigating the effectiveness of oral FA for the 
treatment of prosthetic joint infections in the United States are also underway, as a part of an 
effort to register FA in the United States, since it is yet to be approved by FDA [228]. 
Fusidic acid is available in different conventional dosage forms, including; tablets and 
suspension for oral, cream and ointment for topical and also injection for intravenous 
administration [121]. However, there are challenges that limit the formulation and therapeutic 
efficacy of FA. Due to the hydrophobic nature of FA, it has been classified as a class II drug 
according to the biopharmaceutical classification system (BCS) [229]. When compared to 
highly soluble drugs, poorly soluble drugs not only indicate in vivo challenges, such as 
reduced bioavailability and higher inter-patient variability, but also many in vitro obstacles 
associated with formulations such as restricted choice of delivery techniques and complex 
dissolution testing with low or weak co-relation to in vivo absorption [229-231]. Several 
techniques, such as micronization [232], solubilization [233] and salt formation [234], have 
been explored to solve the problem of low aqueous solubility. Despite the good water 
solubility of FA sodium salt, it precipitates in acidic media and its solubility often appears to 
vary with changes in pH in the gastrointestinal tract. Furthermore, FA binds with high affinity 
to human serum albumin (HSA) under normal conditions, 91% to 98% of FA molecules in 
circulation are bound to HSA [122]. However, it should be used with caution because one of 
the frequent side effects of FA is hyperbilirubinemia/jaundice, which can occur as early as 
two days post treatment [235]. An in vitro and in vivo study confirmed that FA is capable of 
causing significant displacement of bilirubin bound to HSA [236]. This adverse effect is more 
serious in infants as jaundice occurs in 60% to 80% of normal infants in the United States 
[237, 238]. Hence, a strategy that can improve the water solubility and pharmacokinetic 
profiles of FA, as well as reduce its side effects, whilst retaining its antimicrobial activity is 
of significant interest and necessity. 
The drug delivery field using polymers such as polyethylene glycol (PEG), which is 
covalently connected to a drug is known as ―polymer therapeutics‖ [106, 239]. Polymer 
therapeutics have been reported to increase plasma circulation time, reduce side effects and 
increase the therapeutic index of the conjugated drugs. The conjugation of drug molecules 
with polymers such as PEG is one of the most attractive techniques in the drug delivery field 
that can boost the activity of drugs [108]. Moreover, polymer therapeutic prodrugs that have 
the ability to self-assemble into nanosized particles have received considerable attention in 
drug delivery [58]. PEGylation has been reported to be a suitable technique for formulating 
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polymer therapeutics [110, 111], with several products such as Pegasys, Mircera and Cimzia 
being available in the market [107]. Therefore, PEGylation of biopharmaceutics class II drugs 
such as FA could offer a strategic opportunity to improve the therapeutic effects of the drugs. 
PEGylated polymer therapeutics have shown to enhance water solubility of poorly soluble 
drugs, reduce uptake by the reticulo-endothelial system (RES), target the delivery of drugs to 
specific sites of action and reduce HSA binding [47, 108]. In particular, PEGylated irinotecan 
conjugate, a polymer therapeutic that entered phase II clinical trials, showed superior 
anticancer activity, compared to irinotecan alone [240]. The activity enhancement was 
attributed to the combination of enhanced drug solubility, improved biodistribution and the 
enhanced permeability and retention (EPR) effect [241]. 
There are several reported polymer therapeutics for enhancing and improving the activity of 
antibiotics, such as penicillin [112, 113], fluoroquinolones [114-117], aminoglycoside [110, 
118] and sulfonamides [119] using delivery systems developed through polymeric 
conjugation. Although there have been reports of FA conjugation with small molecules in 
order to enhance and broaden its spectrum [123, 124], there are no reports on polymer FA 
conjugation to form a self-assembling polymer therapeutic. Therefore, polymeric conjugation 
of FA with a biodegradable polymer such as PEG, can potentially enhance its aqueous 
solubility, bioavailability and antimicrobial activity. 
Molecular dynamics (MD) simulations are routinely used to provide understanding and 
testing of novel hypotheses at the molecular scale for small molecule drug delivery research 
[242-244]. With recent advances in computational power such simulations can now be used 
in nanomedicine, for instance, to better understand assembly and biological properties of 
nanoparticles, such as protein binding [47, 245]. 
In this study, we report a novel PEGylated FA (PEG-FA), conjugated through a small spacer 
with an amide bond for self-assembly into a nanosystem for simultaneous improved solubility 
and antibacterial activity and decreased HSA binding. Moreover, we report for the first time, 
the quantitative binding of FA, bilirubin and PEGylated FA molecules with HSA using 
microscale thermophoresis (MST). Further, in silico studies were used to evaluate the self-
assembly and binding affinity of PEG-FA to HSA at a molecular level. 
2. Materials and methods 
2.1. Materials 
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Monomethoxy PEG (MW 2,000), FA, 6-aminohexanoic acid (6-AHA), p-
dimethylaminopyridine (DMAP), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (USA). Dichloromethane 
(DCM) was purchased from Merck Chemicals (Pty) Ltd (Johannesburg, South Africa). Di-
tert-butyl dicarbonate (BOC anhydride) was purchased from Sisco Research Laboratories 
Pvt. Ltd (India). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was 
purchased from Merck Chemicals (Germany). For cell culture, cells were purchased from 
Highveld Biologicals (Johannesburg, South Africa). Cell culture reagents were purchased 
from Whitehead Scientific (Johannesburg, South Africa). For haemolytic study, sheep blood 
from United scientific (Durban, South Africa). For bacterial cultures, Mueller-Hinton Broth 
(MHB), Nutrient Broth and Mueller-Hinton Agar (MHA) were purchased from Biolab (South 
Africa). S. aureus (ATCC 25923) and MRSA (SA Rosenbach ATCC BAA 1683) were 
purchased from DLD Scientific (South Africa). Purified water used in the study was 
produced in the laboratory with a Milli-Q water purification system (Millipore corp., USA). 
Bilirubin and HSA were purchased from Sigma-Aldrich (USA). Monolith protein labeling kit 
RED-NHS, MST buffer supplemented with 0.05% Tween 20 and Monolith NT.115 standard 
treated capillaries were supplied by NanoTemper Technologies (Germany). All reagents and 
solvents used in this study were of analytical grade. 
2.2. Synthesis and characterization of PEG-FA 
PEG-FA conjugate was synthesized using Scheme 1. Details of synthesis can be found in the 
supplementary material. 
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Scheme 1. Synthesis of PEG-FA. I) Methanol, room temperature, 24 h; II) EDC, DMAP, DCM, room 
temperature, 24 h; III) TFA, DCM, room temperature, 2 h; IV) EDC, DMAP, DCM, room 
temperature, 24 h. 
2.3. Characterization of the synthesized PEG-FA 
Fourier-transform infrared spectroscopy (FT-IR) spectra of all the compounds were recorded 
on a Bruker Alpha-p spectrometer with a diamond ATR (Germany). Thermal profiles of the 
polymer and the conjugated polymer were determined using differential scanning calorimetry 
(DSC) (Shimadzu DSC-60, Japan) [246]. Samples were loaded on aluminum pans (2 mg) and 
sealed using a crimper, followed by heating under nitrogen flow, at a constant rate of 10 
°C/min to 300 °C. An empty pan was used as a reference. Proton nuclear magnetic resonance 
(
1
H NMR) measurements were performed on a Bruker 400 Ultra shield™ (United Kingdom) 
NMR spectrometer using deuterated chloroform (CDCl3) as a solvent. 
2.4. Solubility studies 
A comparison of the solubility enhancement between FA and PEG-FA was determined using 
a previously reported method [225]. Briefly, a specific amount of FA and PEG-FA was added 
to water in vials at a concentration of 100 µg/mL. The mixture in the vials were kept in an 
isothermal shaker at 37 ± 1.0 °C for 72 h. The undissolved part was filtered through a 
membrane filter (0.22 μm), and centrifuged for 15 min at 3000 rpm. The absorption was 
measured at 285 nm using a UV spectrophotometer (UV-1800, Shimadzu, Japan). The 
samples for solubility studies were prepared in triplicate. 
2.5. In vitro biosafety 
2.5.1. Cytotoxicity and cell viability 
The in vitro cell viability of the conjugated PEG-FA was evaluated and compared to FA 
using the MTT assay [150]. Three different cell lines were used in this study: human 
embryonic kidney 293 (HEK 293) cells, Michigan Cancer Foundation-7 (MCF-7) breast 
cancer cells and human cervical cancer (HeLa) cells. All three cell lines were seeded at a 
concentration of 2.5 x 10
3 
cells/well into a sterile 96-well plate containing 100 µL DMEM, 
10% fetal bovine serum (FBS), 1% pen-strep-fungizone and 1% L-glutamine and incubated 
for 24 h at 37 °C in a CO2 humidified incubator. Thereafter, different concentrations of PEG-
FA and FA (20, 40, 60, 80 and 100 μg/mL) were added and incubated for a further 24 h. 
After the 24 h incubation period, the media were substituted with 100 μL of MTT solution (5 
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mg/mL in PBS) per well and incubated for 4 h. The supernatant was then aspirated and 
formazan crystals were solubilized using 100 μL of dimethyl sulfoxide. A microplate 
spectrophotometer (SpectrostarNano, Germany) was used to read absorbances at 540 nm 
(proportional to the number of live cells). The study was performed in hexaplicate and the 
formula below was used to calculate the percentage cell viability. 
                 (
                     
                       
)        
2.5.2. Haemolysis  
A previously reported method was used for the determination of percentage hemolysis [193]. 
Briefly, freshly collected sheep blood was washed three times with autoclaved phosphate 
buffer saline (PBS, pH 7.4), followed by centrifugation at 2800 rpm for 5 min. PEG-FA was 
diluted with PBS to a concentration ranging from 0.05 to 0.5 mg/mL for each sample. The 
red blood cell (RBC) suspension (0.2 mL) was added to 1.8 mL of each sample and left for 
incubation at 37 °C for 30 min. Thereafter, the samples were centrifuged at 3000 rpm for 10 
min. Spectrophotometric readings of the supernatant of each sample at different 
concentrations were taken for the determination of haemoglobin release. To obtain 0% and 
100% haemolysis, 0.2 mL of RBC suspension was added to 1.8 mL PBS and distilled water, 
respectively. The degree of haemolysis was calculated using the formula below. 
             (
         
           
)        
Where, ABS100 and ABS0 are the absorbances of the solution at 100% and 0% haemolysis, 
respectively. The results of triplicate measurements were used. 
2.6. Preparation of PEG-FA nanoparticles 
Self-assembled PEG-FA NPs were prepared by the solvent evaporation method [143]. 
Briefly, PEG-FA (50 mg) was dissolved in THF (0.5 mL) and slowly added to water (10 mL) 
dropwise. The formed emulsion was stirred for 24 h at room temperature to ensure complete 
evaporation of the solvent. Thereafter, the volume was adjusted to 10 mL. The self-assembled 
PEG-FA nanosystem was further characterized. PEG-FA nanoparticles were prepared in 
triplicate. 
2.7. Characterization of PEG-FA nanoparticles 
2.7.1. Size, polydispersity index (PDI), zeta potential (ZP) and morphology  
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The molecular self-assembly of PEG-FA conjugate into its nanostructures was characterized 
using the dynamic light scattering (DLS) technique to determine their average size, PDI and 
ZP. Appropriate dilutions of the formula were made using distilled water. Measurements 
were recorded at room temperature using a Zetasizer Nano ZS90 (Malvern Instruments, UK) 
fitted with a 633 nm laser at 173° detection optics. All parameters were analyzed in triplicate. 
To observe the morphological structure of PEG-FA nanoparticles, a High-Resolution 
Transmission Electron Microscope (HRTEM, JEOL 2100) was used. 
2.7.2. In silico study of PEG-FA self-assembly 
2.7.2.1. All-atom molecular dynamic simulations of PEG-FA self-assembly 
Molecular―dynamic (MD) simulation is a widely applied technique in the field of drug 
delivery to achieve different tasks, such as understanding the drug interaction with proteins, 
membranes and polymers. The spontaneous self-assembly of PEG-FA was studied using MD 
simulations to understand the mechanism and identify the type of interactions that played a 
crucial role in self-assembly. The synthesized conjugate (PEG-FA) structure composed of 
single FA attached through single 6AHA to PEG polymer compromising of seven repeating 
monomer units of ethylene glycol (EG), was drawn with ChemDraw professional software 
[247]. The Chimera tool was used for random insertion of six molecules of PEG-FA complex 
[161]. The LEAP module implemented in AMBER 14 was used to combine, neutralize and 
solvate the system by adding hydrogen atoms, chloride and sodium ions and suspending them 
in an orthorhombic box of TIP3P water molecules such that all atoms were within 10 Å of the 
box edges [248]. The system contained a total of 5820 water molecules and 6 molecules of 
PEG-FA. The system was minimized for 2500 steps with applied restraint of 100 kcal/mol Å, 
followed by 1000 steps of full minimization. The system was then gradually heated from 0 
°K to 300 °K for 50 ps such that they maintained a fixed number of atoms and fixed volume 
(NVT) with a potential harmonic restraint of 10 kcal/mol Å and collision frequency of 1.0 ps
-
1
. The system was then equilibrated without restraint at a temperature of 300 °K at a constant 
pressure of 1 bar using the Berendsen barostat. This was followed by MD production for 40 
ns per system, in which the SHAKE algorithm was used to constrict the bonds of hydrogen 
atoms [147]. All the MD simulations were carried out using the GPU amber 14 software 
package [148]. 
2.7.2.2. Post-dynamic analysis 
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To determine the binding free energy, the trajectory generated after MD simulation was saved 
every 1 ps, followed by analysis using the CPPTRAJ [165] module employed in AMBER 14 
suite. All plots, visualizations and graphical representations were completed using Microcal 
Origin tools [249] and Chimera [161], respectively. 
2.7.2.3. Binding free energy calculations 
Binding free energy calculations is an important endpoint method that may be used to 
elucidate the mechanism of binding between a ligand and protein, including both enthalpic 
and entropic contributions [250, 251]. To estimate the binding affinity of the system, the free 
binding energy was calculated using the Molecular Mechanics/Generalized Born Surface 
Area method (MM/GBSA) [252]. Binding free energy was averaged over 1000 snapshots 
extracted from the 10 ns trajectory. The free binding energy computed by this method for 
each molecular species (complex, ligand, and receptor) can be represented as: 
                                 ( ) 
                       ( ) 
                   ( ) 
            ( ) 
                       ( ) 
where: 
Eele  Electrostatic potential energy from Coulomb forces 
Egas  Gas-phase energy (based on FF14SB force field terms) 
Eint  Internal energy 
EvdW  van der Waals energy 
Gsol  Solvation free energy 
GGB  Polar solvation energy 
GSA  non-polar solvation energy 
S  Total entropy of solute 
SASA  Solvent accessible surface area (water probe radius of 1.4 Å) 
T  Total entropy of temperature 
The Egas was directly assessed from the force field terms. The Gsol, was assessed from the 
energy involvement from the GGB, and non-polar states (G). The GSA was determined from 
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SASA using a water probe radius of 1.4 Å, whereas the GGB contribution was assessed by 
solving the GB equation. S and T symbolize the total entropy of the solute and temperature, 
respectively [252]. 
2.8. Determination of the binding affinity of FA, bilirubin and PEG-FA to HSA 
2.8.1. In silico study of the binding affinity  
2.8.1.1. Molecular docking study 
This study was conducted to study the effect of PEGylation of FA on the binding of HSA in 
comparison with bilirubin at the molecular level. This was performed using molecular 
modeling environment (MOE) to evaluate the binding affinities and the best binding positions 
between the 3 compounds (FA, bilirubin and PEG-FA) and the sub-domain IB of HSA (Fig. 
1). 
 
Fig. 1. The 3-D crystal structure of human serum albumin (PDB code: 2VUE). 
Docking studies were performed using the MOE 2008.10 (MOE source: Chemical 
Computing Group Inc., Quebec, Canada, 2008). First, a Gaussian contact surface was drawn 
around the binding site. The surface of the molecule is occupied by van der Waals attraction 
forces (filling in solvent inaccessible gaps). Docking studies were performed to determine the 
binding free energy of FA and synthesized PEG-FA conjugate within the macromolecules. 
Simply, we performed molecular docking with two PEG-FA molecule sseparately with a 
small PEG chain (2 and 7 monomer of EG). Dock Scoring in MOE software was conducted 
using the London dG Scoring feature and it was improved using two separate refining 
methods, the Force-field and Grid-Min posing to ensure that the refined poses met the 
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required specified conformations. We allowed rotatable bonds; the best 10 poses were 
retained and analyzed for the binding pose with the best score. 
2.8.1.2. Preparation of the ligands and HSA 
The ligand compounds involved in this study were tested for their binding affinity to the sub-
domain IB of HSA. The Molecule Builder method in MOE has been used to create a three-
dimensional model of the structures. Energy minimization was carried out through Force-
field MMFF94x Optimization using a gradient of 0.0001 for the determination of low energy 
conformations with the most suitable (lowest energy) geometry. The crystal structure of HSA 
in complex with 4Z,15E-bilirubin was retrieved from the Protein Data Bank [253] (PDB 
code: 2VUE) [254]. Hydrogen atoms and partial loads have been applied with the protonation 
3D application in MOE. This application is used to assign ionization states and place 
hydrogen atoms in the macromolecular structure.  
2.8.1.3. The binding affinities of the FA and the synthesized PEG-FA conjugate to HSA 
proteins 
Molecular docking analysis was performed to identify the interactions between the ligands 
and HSA, as well as to compare the binding affinities of FA and PEG-FA conjugate towards 
the target sub-domain IB HSA. For docking calculations, the protein structure was first split 
from the inhibitor molecule and improved by molecular minimization with added hydrogen 
atoms. Docking calculations have been conducted using default variables for the MOE 
program. The binding affinity was measured by binding free energies (S-score, kcal/mol) and 
hydrogen bonds. All the synthesized conjugates in addition to FA were docked in the same 
groove of the sub-domain IB binding site of the native co-crystallized‖bilirubin-ligand. 
2.8.2. Microscale thermophoresis binding affinity studies 
Based on the in silico confirmation, MST studies were undertaken to quantitatively elucidate 
the difference in binding. The binding parameters between FA, bilirubin and PEG-FA with 
HSA were measured using MST on a Monolith NT.115 (Germany) [47]. Labeling of HSA 
was carried out using the Monolith protein labeling kit RED-NHS according to the 
manufacturer‘s instructions. MST assay buffer supplemented with 0.05% Tween 20 was used 
to dilute the labeled HSA to 100 nM. A series of 16 dilutions (1:1) using the same buffer 
solution of the ligands (FA, bilirubin and PEG-FA) were prepared with starting concentration 
of 300 μM. Equivalent volume of the labeled HSA was added to each of the dilutions and 
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incubated for 10 min, then loaded into Monolith NT.115 Standard Treated Capillaries (Nano 
Temper Technologies). The measurement of the MST trace was carried out using a Monolith 
NT.115 instrument (Nano Temper Technologies) at a temperature of 27 °C. Parameters were 
adjusted to 40% MST and power 20% LED power. The strength of binding was evaluated 
using MO-Affinity analysis software version 2.1.3 (Nano Temper Technologies). The results 
of triplicate measurements were used to calculate the dissociation constant, Kd. 
2.8.3. HSA protein adsorption studies 
Human serum albumin adsorption studies were performed according to a previously reported 
protocol [47, 255]. The self-assembled PEG-FA NPs were incubated in a solution of 400 
μg/mL of HSA and stirred vigorously for 2 h at 37 °C. The NPs were then centrifuged 
(14,000 rpm, 4 °C for 20 min) to remove any unabsorbed proteins. The samples were then 
diluted, and the Zetasizer was used to analyze the size and surface charge. 
2.9. In vitro antibacterial activity 
The broth microdilution method was used to determine the minimum inhibitory 
concentrations (MICs) of FA and PEG-FA against S. aureus and MRSA [153]. Briefly, an 
overnight culture in nutrient broth at 37 °C of S. aureus and MRSA, placed in a shaker 
incubator, was diluted to 0.5 McFarland standard, using a DEN-1B McFarland densitometer 
(Latvia). In a 96-well plate, a specific volume of MHB was added, followed by the addition 
of an equal volume of bare FA solution (positive control), and PEG-FA in the first well, then 
they were serially diluted. Subsequently, S. aureus and MRSA were further diluted to 5 × 10
5
 
colony-forming units per mL (CFU/mL) and added to the 96-well plate containing the 
serially diluted samples and MHB. The studies were performed in triplicate. The broth 
mixture was incubated for 24 h in a shaking incubator at 37 °C, then spotted on MHA plates, 
and incubated for 24 h at 37 °C to calculate the MICs. 
2.10. Statistical analysis 
The results were stated as mean ± standard deviation (SD), and the data analysis was carried 
out using GraphPad Prism
®
 5 (Graphpad Software Inc., USA). The multiple comparison test 
and One-way ANOVA from Bonferroni were used to evaluate the results, and the difference 
was considered significant when p < 0.05. 
3. Results and discussion 
3.1. Synthesis of PEG-FA conjugate 
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PEG was chosen as a conjugating polymer with FA due to its unique properties, such as high 
water solubility, biocompatibility, lack of toxicity, low immunogenicity and presence of one 
or two functionalizable hydroxyl groups. In this study, we used PEG, which has only one 
terminal hydroxyl group. The preliminary work involved conjugation of FA to PEG directly 
without the use of a linker, but the reaction was not successful. A similar problem with PEG 
conjugation with other drugs was resolved using a small linker or spacer [256]. Since primary 
amines are more reactive than alcohol groups (-OH), a linker with free amine groups was 
chosen to conjugate FA and PEG [257]. Amino acids are well-known spacers that have been 
used to conjugate PEG with different peptides, proteins and non-protein drugs [256, 258]. A 
derivative of amino acid lysine (6-aminohexanoic acid) was used as a spacer between PEG 
and FA. The first step was to protect the amino group of the amino acid using BOC 
protection as described in Scheme 1, to synthesize compound I. The second step was an 
esterification reaction, to conjugate PEG with compound I, to produce the PEG-spacer 
conjugate (compound II). A further cleaving step was carried out to deprotect the terminal 
amine group (compound III). The last step was to conjugate the carboxylic group of FA with 
the amine group of compound III, through amidation reaction to get the final PEG-FA 
(compound IV). The polymer drug conjugate product (PEG-FA) was verified and fully 
characterized using FT-IR, DSC and 
1
H NMR, and compared to the individual spectra of FA 
and PEG-spacer. 
3.2. Characterization of PEG-FA 
FT-IR spectra of FA, PEG-6AHA and PEG-FA have been provided in the supplementary 
material (Fig. S1). The formation of amide bond between FA and PEG-6AHA was confirmed 
by the appearance of a new peak at 1640 cm
−1
, which is characteristic of a stretching 
carbonyl group (C = O). Another peak was observed at 1510 cm
−1
 due to bending of (N-H) 
bond [259]. These results provided preliminary confirmation of successful synthesis of drug-
polymer conjugate (PEG-FA). DSC can also provide evidence for the successful synthesis of 
PEG-FA [260]. From the thermograms (Fig. 2A and 2B), the PEG-6AHA polymer shows 
two endothermic peaks at 57.4 °C and 204.9 °C, while FA shows an endothermic peak at 
191.2 °C, which corresponds to the melting point of FA (Fig. 2A). The DSC thermogram of 
the final polymer drug conjugate PEG-FA exhibited a sharp endothermic peak at 54.4 °C, 
similar to the main peaks in PEG-6AHA polymer. Furthermore, there are two other small 
peaks at 225.2 °C and 281.2 °C, whereas the peak for the melting point of FA disappeared. 
This confirms the conjugation of FA to PEG and absence of the free FA. The results obtained 
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from FT-IR and DSC were further verified using 
1
H-NMR analysis. Fig. 3 shows the 
1
H-
NMR peaks for FA, PEG-6AHA and the final product (PEG-FA). In both PEG-6AHA and 
PEG-FA, the repetitive ethylene protons can be identified at 3.6 ppm. The peaks that 
appeared between 2.3 ppm and 2.9 ppm in the spectra of PEG-6AHA and PEG-FA were 
attributed to the methylene protons (-CH2-) of 6AHA, thus confirming the esterification 
between the PEG and 6AHA (Fig. 3). Further, the presence of protons corresponding to FA 
that appeared between 0.5 ppm and 2.5 ppm in the spectrum of PEG-FA confirmed the 
successful conjugation of PEG-6AHA to FA. 
 
Fig. 2. DSC thermogram of A) 6AHA, PEG and PEG-6AHA. B) PEG-6AHA, FA and PEG-FA. 
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Fig. 3. 
1
H-NMR spectra of FA, PEG-6AHA and PEG-FA in CDCl3. 
3.3. Solubility studies 
In this study we aimed to measure solubility by measuring the dissolved compound rather 
than measuring the turbidity of the undissolved particles. Since absorption spectrum of PEG-
FA was observed at 285 nm, solubility was measured at same wavelength [225]. Solubility 
studies using UV absorbance showed that PEG-FA was almost completely dissolved in water 
(99.6 ± 3.4 %), while only 4.1 ± 0.2 % of FA was soluble (Fig. 4). There was a 25-fold 
increase in solubility of PEG-FA when compared to the bare drug (p< 0.05). As previously 
mentioned, FA is a class II drug, according to BCS. The drugs belonging to this class suffer 
from poor aqueous solubility and low dissolution rates, which limits their oral bio-absorption 
and causes difficulty in formulating parenteral dosage forms [229, 231]. This phenomenon of 
solubility enhancement could be attributed to the PEGylation effect, as reported in the 
literature for other drugs [260, 261]. Furthermore, the self-assembly of PEG-FA into NPs 
could also contribute to solubility enhancement, as the solubility of particles is inversely 
proportional to their radius, according to Ostwald–Freundlich effect [262, 263]. In 
comparison with FA nanosuspension that was previously prepared by nanoprecipitation using 
various surfactants [246], the self-assembled PEG-FA NPs in our study showed advantageous 
features, such as superior solubility and smaller size. Moreover, a nanosuspension faces the 
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major drawback of nucleation and particle growth, which could be overcome by PEG-FA 
self-assembled NPs [264]. In another study, micelles were formulated with an amphiphilic 
dendrimer to enhance FA solubility [265]. However, encapsulation efficiency achieved was 
only 25%, whereas PEG-FA NPs overcame this obstacle with FA conjugated directly to the 
polymer without reducing the antibacterial effect. The significant increment in the aqueous 
solubility of FA will be highly beneficial for its bioavailability, as it will facilitate drug 
partitioning through biological membranes. Therefore, the enhanced water solubility of FA 
owing to PEGylation could potentially improve the activity of the drug. 
 
Fig. 4. The solubility of FA and PEG-FA in water, n=3. 
3.4. In vitro biosafety 
3.4.1. Cytotoxicity and cell viability 
The cytotoxic effect of the synthesized PEG-FA was determined via the in vitro MTT 
cytotoxicity assay. The MTT assay measures the number of healthy, living cells based on 
enzymatic conversion of the yellow tetrazolium salt into the purple formazan crystal by living 
mammalian cells. The amount of formazan crystals produced is proportionate to viable cells 
present [150]. The results showed that cell viability ranged from 84% to 99%, across all 
concentrations on all three tested cell lines (Fig. 5). This is in accordance with the ISO norm 
for biomedical products (>75% cell viability) [190]. In this study, no dose-dependent toxicity 
within the concentration range to any of the three cell lines was reported for PEG-FA, while 
FA showed some cytotoxicity at the highest concentration (100 µg/mL) towards HEK 293 
and HeLa cells with viability of 53% and 62%, respectively. FA is known to have anti-
proliferative activity against some human cell lines. For this reason, FA and its chemical 
derivatives have been investigated as promising anticancer molecules [266, 267]. This result 
confirms the biocompatibility and biosafety of PEG-FA, which correlate with other reports 
showing a decrease in cytotoxicity of other drugs or dendrimers when attached to PEG chains 
[108, 110, 268]. 
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Fig. 5. MTT assay for evaluation of cytotoxicity of A) PEG-FA and B) FA, against HeLa, HEK 293 
and MCF-7 cell lines. 
3.4.2. Haemolysis 
Blood compatibility is an essential factor for all intravenously administered pharmaceuticals 
to ensure they do not possess haemolytic activity [192]. Due to the nanosize, positive charge 
and unique physicochemical characteristics of NPs, interference with RBCs is likely to 
happen more than the small-molecule drugs. Therefore, an early preclinical study to confirm 
their biocompatibility with the blood constituents is essential [193]. Red blood cells collected 
from sheep blood was used to evaluate the haemolytic properties of PEG-FA conjugate and 
bare FA (Fig. 6A and 6B). Among the different concentrations used in the study (Table 1), 
the highest concentration (250 µg/mL) of PEG-FA and FA resulted in ˂0.3% and 8.6% 
haemolysis of RBCs, respectively. However, the FA plasma concentration that is sufficient 
for antibacterial activity is reported to be 15 - 30 µg/mL [228, 235], which is still within the 
non-heaemolytic concentration for both FA and PEG-FA. This result further confirms the 
improved biosafety profile and non-haemolytic nature of PEG-FA in comparison to bare FA. 
Table 1. Haemolysis (%) for different concentrations of FA and PEG-FA, PBS (pH 7.4) and distilled 
water. 
Concentration (µg/mL) 
Haemolysis (%) 
FA PEG-FA 
7.8 0 0 
15.6 0.22 0.18 
31.2 0.78 0.24 
62.5 2.28 0.24 
125 5.28 0.24 
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250 8.6 0.25 
PBS (pH 7.4) 0 0 
Distilled water 100 100 
 
 
Fig. 6. Haemolysis assay of FA and PEG-FA A) Images of RBCs treated with FA and PEG-FA at 
various concentrations. B) % of haemolysis after exposure to various concentrations of FA and PEG-
FA. Data are expressed as mean ± SD, n=3. 
3.5. Preparation and characterization of PEG-FA nanoparticles 
3.5.1. Size, PDI, ZP and morphology 
Recently, drug polymer conjugates with amphiphilic properties that are able to self-assemble 
into well-defined nanostructures in aqueous solutions are showing potential for enhancing 
drug delivery [58, 260]. PEG-FA nanoparticles were prepared using a simple solvent 
evaporation technique. Following spontaneous evaporation of the solvent, FA and PEG 
serving as hydrophobic core and hydrophilic shell, respectively could have directed the self-
assembly of amphiphilic PEG-FA under aqueous environment to form NPs. The molecular 
self-assembly of PEG-FA conjugate was characterized via a Zetasizer and HRTEM. The 
results revealed that the average hydrodynamic diameter of the self-assembled nanosystem 
was 149.3 ± 0.21 nm with a PDI of 0.267 ± 0.01 and surface charge of 5.97 ± 1.03 mV. The 
size and morphology of the assembled NPs were also investigated under HRTEM (Fig. 7A). 
The images showed that PEG-FA nanoparticles had a spherical morphology and were 
dispersed homogeneously with an average particle size found to be ~100 nm. This result 
corroborates well with obtained small PDI value (0.267 ± 0.01), indicating a high degree of 
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particle homogeneity. The size of the nanoparticles observed by HRTEM appeared to be 
smaller compared to DLS (Fig. 7B), because DLS represents average hydrodynamic diameter 
of particle, while HRTEM images relates to shrunken dehydrated particles after water 
evaporation [269]. Generally, nanosized structures have higher efficacy for cellular uptake, 
which will assist in targeting bacterial infected sites [171, 270]. The positive surface charge 
of PEG-FA NPs might encourage interactions with the negatively charged elements on the 
bacterial cell wall and create strong multivalent electrostatic-mediated binding [271]. Since 
PEG is known as a water-based stabilizing moiety, the PEGylated surface of the NPs would 
induce extra stability through steric stabilization, thus providing sufficient colloidal stability 
to the system [272, 273]. The results are comparable to other reported polymeric drug 
conjugates that self-assemble into nanostructures with improved therapeutic outcomes. In one 
such report, PEGylated sulfasalazine (treatment for inflammatory bowel disease) showed 
enhanced solubility and self-assembled into micellar structures with an average size of 
212.9 ± 21.7 nm, and proved to be an efficient carrier for colonic drug delivery [261]. Unlike 
small drug molecules that get distributed throughout the whole body organs leading to 
undesirable side effects [58], NPs with an appropriate size and drug composition possess 
distinct physicochemical properties. These include longer circulation half-life and differential 
biodistribution profile compared with the free drug counterpart [58, 274]. Therefore, PEG-FA 
nanoparticles could hold great promise for enhancing the delivery of antibiotics. 
 
Fig. 7. A) Morphology of the self-assembled PEG-FA conjugate from HRTEM. B) Histogram for 
sample measurement showing size distribution measured via DLS. 
3.5.2. In silico studies for self-assembly of PEG-FA 
3.5.2.1. All-atom MD simulations of PEG-FA self-assembly 
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Molecular―dynamic simulations were performed to study the mechanism and forces that 
contributed to the self-assembly of the PEG-FA nanosystem. The total binding free energy 
was calculated to gain insight into the binding energetics of PEG-FA conjugates. The 
MM/GBSA program in AMBER was used to calculate the binding free energies by extracting 
snapshots from the trajectories. 
Table 2. The binding energies (kcal/mol) of PEG-FA conjugates computed from the MD trajectories 
 Energy Components (kcal/mol) ± SD 
 Δ EvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
PEG-FA 
-65.55 ± 0.51 -11.31 ± 
0.18 
-76.87 ± 0.63 35.01 ± 
0.30 
-41.85 ± 0.36 
-55.24 ± 1.86 -13.72 ± 
0.57 
-68.96 ± 2.39 31.92 ± 
1.10 
-37.04 ± 1.31 
-34.47 ± 1.33 -7.73 ± 0.37 -42.21 ± 1.66 19.34 ± 
0.72 
-22.86 ± 0.95 
-63.70 ± 1.65 -14.42 ± 
0.50 
-78.13 ± 2.09 37.67 ± 
1.03 
-40.45 ± 1.08 
-47.78 ± 1.82 -10.04 ± 
0.46 
-57.83 ± 2.23 29.09 ± 
1.10 
-28.73 ± 1.15 
-69.71 ± 0.66 -24.10 ± 
0.24 
-93.81 ± 0.85 42.58 ± 
0.38 
-51.22 ± 0.49 
 
From Table 2, we can conclude that binding energy components showed that vdW energy, 
non-polar energy and electrostatic energies led to the overall highly favorable binding energy, 
however polar solvation energy appeared to be highly unfavorable. 
It was observed that PEG-FA amphiphilic molecules started to assemble within a few 
nanoseconds of simulation (Fig. 8). Simulation data revealed that at ~20 ns, four molecules 
were aggregated and at 32 ns, five molecules were formed. We observed that total 
aggregation was formed at 40 ns. This arrangement included the hydrophilic portions (PEG) 
of the PEG-FA conjugate facing the outside of the aggregates and is in contact with water 
molecules, while the hydrophobic segment (FA) was sandwiched in the middle and tend to be 
less exposed to water (Fig. 8C and 8D). This aggregation could have been the possible 
arrangement that resulted in the formation of the NPs. Literature shows this arrangement is a 
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typical intermediate arrangement before the formation of NPs [275, 276]. The general 
structure of PEG-FA conjugate is a solvent-(philic-phobic) type structure that contains a 
hydrophobic part connected to a hydrophilic polymer. The philic-phobic structures have 
shown the ability to self-assembly in solution to form complex structures such as spherical 
micelles, cylindrical micelles, NPs and vesicles [276, 277]. These structures have been 
successfully employed in drug delivery. From a thermodynamic point of view, the self-
assembled structure built from philic-phobic conjugate in solution relies heavily on the 
balance of three free energy contributions: chain stretching in the core, interfacial tension and 
repulsion interaction between coronal chains [278]. 
The stability of the simulated system was investigated by evaluating the differences in the 
root-mean-square deviation (RMSD) with respect to the minimized structure, as well as the 
potential energy of the complex during the simulation time. The calculation of the RMSD is 
considered as the time point when the conformation changes. In order to ensure a 
comprehensive investigation of a well-relaxed and balanced system, RMSD, kinetic energy 
and potential energy were monitored along the MD simulation. The system under study was 
properly balanced and conformational stability was observed throughout the simulations (Fig. 
S2). Overall, the results of this study supported the fact that PEG-FA could self-assemble to a 
stable aggregate. 
 
Fig. 8. Representation of the self-assembly of PEG-FA conjugates via MD simulation at different 
time points (t). 
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3.6. Determination of the binding affinity on HSA 
3.6.1. Molecular docking study 
This study was conducted to understand the binding of FA to HSA and the interaction with 
bilirubin binding, and to study the effect of PEGylation of FA on the HSA binding at a 
molecular level. Fusidic acid provided the best docking score based on the free energy 
binding (-30.10 kcal/mol), which revealed a stronger interaction between FA and HSA 
compared to the 4Z,15Z-bilirubin, which exhibited a lower docking score (-14.95 kcal/mol) 
(Fig. 9 A1 and 9 A2). This correlates with previous literature, which reports the competitive 
binding of FA with 4Z,15Z-bilirubin for the same binding site on HSA [236, 254], due to the 
hydrophobicity and hydrogen bond formation of FA with the binding site residues on HSA. 
Besides hydrogen bonds and electrostatic interactions, no secondary structure change upon 
FA binding to the receptor was observed. Fusidic acid adopts an L-shaped conformation and 
occupies the binding pocket of sub-domain IB in a way very similar to 4Z,15Z-bilirubin (Fig. 
9 B1 and 9 B2). The side-chain hydroxyl of TYR 161 creates equal distance hydrogen bonds 
(3.3 Å) with the two hydroxyl groups that are expected from the FA steroid rings. At the 
other end of the drug molecule, the hydrocarbon tail of methyl-heptanoic acid group is 
projected into the deeper part of the binding pocket. The acetyloxy and carboxylate groups of 
FA are positioned at the entrance of the pocket, where hydrogen bond interactions with 
ARG117 and ARG186 occur. Notably, the two side-chains of Arg are significantly reoriented 
in order to establish these specific interactions with the drug. An upward rotation of the side-
chain of ARG117 by approximately 40° is required to provide room for the increased bulk of 
the steroid moiety of FA. In contrast, when the synthesized PEG-FA was docked with 2 EG 
monomers (2-PEG-FA), significant weak contacts with binding site amino acid residues 
ARG186 and ARG 117 were observed. Also, it showed unfavorable contact with Ala 126, 
Phe 143, Lys 190, Leu 115, Lys 137 and Leu 139 with very low docking score (-6.85 
kcal/mol) (Fig. 9 C1and 9 C2). Further docking with longer PEG polymer conjugate using 7 
PE monomers (7-PEG-FA) did not show any binding or inter-molecular interactions at the 
binding site with a negligible docking score (-2.93kcal/mol) (Fig. 10). Therefore, the ligand 
interaction binding has shown a weak conformation change especially at the binding site. 
Accordingly, as the PEG chain increased, the interaction of ligand decreased at the HSA 
binding pocket. Hence, since the average molecular weight of PEG that was used for 
synthesis is 2000 g/mol, the conjugate will be unfavorable to fit the binding pocket. This 
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indicates the potential of PEG to reduce the affinity of FA binding to HSA, and thus 
preventing bilirubin displacement. 
 
Fig. 9. Molecular visualization of bilirubin, FA and 2-PEG-FA at the sub-domain IB of HSA [A1], 
[B1] and [C1], respectively. Inter-molecular interactions between bilirubin, FA and 2-PEG-FA with 
sub-domain IB of HSA are shown in [A2], [B2] and [C2], respectively. 
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Fig. 10. Structural orientation of the 7-PEG-FA at the sub-domain IB of HSA showing the 
unfavorable binding site.  
3.6.2. Microscale thermophoresis binding affinity studies 
Microscale thermophoresis is a relatively new quantification technique for biomolecular 
interactions. The technique is based on the gradient change in sample temperature induced by 
infrared (IR) laser, causing thermophoresis of the molecules, which can be detected and 
quantified using the change in the normalized fluorescence [279]. MST offers an elastic, 
robust and fast method for molecular interaction studies. A constant concentration of the 
labelled HSA protein was incubated with increasing concentrations of the test samples (FA, 
bilirubin and PEG-FA). Thermophoresis was then induced and detected due to a created 
temperature gradient by the IR laser. The strength of binding was evaluated by calculating the 
dissociation constant Kd. The smaller the Kd, the stronger is the binding force. Table 3 
represents the Kd value for each material when they were tested for binding with HSA. FA 
showed a Kd value of 120.03 ± 0.53 µM, which is in good agreement with the Kd value 
derived from the surface plasmon resonance method reported for FA binding with HSA 
[280]. This Kd value is 1.7-fold lower than the bilirubin Kd value (p= 0.0006) and 
approximately 120-fold lower than PEG-FA (p<0.0001), which can be interpreted as 
strongest binding properties to HSA protein. Moreover, this result is in accordance with 
literature reports for FA binding to HSA and interaction with the binding of bilirubin, which 
showed that FA is bound strongly and competitively with bilirubin to HSA [236]. 
Conversely, PEG-FA showed an inflated value of 14999 ± 1.36 µM for Kd; this value is 
barely enough to conclude binding (Fig. 11), which is similar to previously reported study for 
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the binding affinity of PEG to HSA using MST [47]. Fig. 11 illustrates the Fnorm % curve 
against the concentration of FA, bilirubin, and PEG-FA from MST experiments. PEG-FA 
curve is a nearly straight line and not showing any dose dependant response in comparison to 
FA and bilirubin. The inhibition of PEG-FA binding to HSA is due to the steric hindrance of 
PEG polymer [281]. This evidence supports the inhibition of binding affinity to HSA for the 
novel PEGylated FA, which will prevent bilirubin displacement and decrease the risk of 
jaundice in infants. Furthermore, the binding affinities of the different molecules to HSA that 
was obtained from this MST study are in line with the calculated binding energies from the 
MD study. 
The MST results were further confirmed by a Zetasizer, where the self-assembled PEG-FA 
conjugate was incubated with HSA, and its effect on the size, PDI and ZP were investigated 
[47, 282]. There was no significant impact on the physical characteristics of the nanosystem 
after incubation of PEG-FA NPs with HSA (Table 4). This could be attributed to the PEG 
forming a shell around the nanostructure, which is considered not to bind with HSA [47], 
suggesting long circulating and stealth offering capabilities to the NPs [255]. Furthermore, 
these results also provide proof of concept that PEG-FA NPs could remain stable in serum 
environment by not binding to human serum albumin and maintaining its structural integrity 
[283]. 
Table 3. Binding affinity parameters of FA, bilirubin and PEG-FA with HSA protein.  
 
Name Kd (µM) ± SD Response amplitude Unbound Bound 
HSA + FA 120.03 ± 0.53 6.953 931.697 924.744 
HSA + Bilirubin 215.8 ± 0.30 5.263 932.620 927.357 
HSA + PEG-FA 14999 ± 1.36 0.568 960.265 960.833 
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Fig. 11. A) The plot of the normalized fluorescence Fnorm (%) vs. the concentration of FA, bilirubin, 
and PEG-FA from MST experiments. Data were derived from the T-Jump signal. Lines represent fits 
of the data points using the Kd model. B) Quantitative comparison of the different ligands shown in 
(A) to the HSA in fraction bound, (n=3). 
Table 4. The effect of HSA on self-assembled PEA-FA conjugate after incubation (n=3). 
Sample size (nm) PDI ZP (mV) 
Before 146.4 ± 0.8 0.225 ± 0.01 8.11 ± 1.2 
After 129.7 ± 1.8 0.261 ± 0.01 6.02 ± 1.5 
 
3.7. In vitro antibacterial activity 
Following the modification of FA to PEG-FA, carboxyl groups were converted to amide 
bonds to couple FA to PEG. The antibacterial activity of FA could be deactivated by this 
coupling. In order to prove that modified FA was still available to inhibit bacterial growth 
after hydrolysis, in vitro antibacterial activity of PEG-FA conjugate against S. aureus and 
 
116 
 
MRSA was determined. The broth dilution method was employed and MICs were calculated 
for bare FA (control) and the PEG-FA conjugate. The results in Table 5 show the MIC 
values in μmol/L for FA and PEG-FA against S. aureus and MRSA. PEGylation increased 
the molecular mass by approximately 5-6 times [284]. After 24 h, the MIC values for FA 
against both S. aureus and MRSA were 15.119 μmol/L, whereas PEG-FA had MIC values of 
5.936 μmol/L against both the tested bacterial strains displaying 2.5 fold improved 
antibacterial activity. After 48 h, there was 1-fold reduction in MICs for both FA 
(30.239μmol/L) and PEG-FA (11.873) against S. aureus and MRSA, and the trend was 
continued until the studied time period of 72 h. Therefore, PEGylated FA showed enhanced 
antibacterial activity against both S. aureus and MRSA compared to FA, with 2.5-fold 
reduced molar MIC values. The Modification of FA through PEGylation to improve its 
solubility could have adversely affected the activity of FA, since some studies have reported 
a reduction in the activity of polymer conjugated antibiotics [284-286]. However, in our 
study, this modification led to better antibacterial activity. This improved antibacterial 
activity could be due to the smaller size of the nanoparticles and the electrostatic attraction 
between the positively charged PEG-FA NPs and the oppositely charged bacterial cell 
membrane [57, 287]. The enhanced FA activity via polymeric conjugation with PEG and 
self-assembly into NPs underlines PEGylation as a promising strategy to develop novel 
antibacterial delivery systems to address the crisis of deterioration of new antibiotics. 
Table 5. MIC values for bare FA and PEG-FA. 
Time (h) 24 48 72 24 48 72 
 S. aureus (MIC μmol/L) MRSA (MIC μmol/L) 
FA 15.119 30.239 30.239 15.119 30.239 30.239 
PEG-FA 5.936 11.873 11.873 5.936 11.873 11.873 
The values are expressed as mean, n=3. 
4. Conclusion 
Recently, there has been a surge of interest in the development of novel drug carrier systems 
for antibiotic delivery. In this study, a novel PEGylated FA was successfully synthesized and 
structurally characterized. In vitro cytotoxicity and haemolysis studies confirmed the 
biosafety of the synthesized PEG-FA with it being superior to FA. The synthesized PEG-FA 
conjugate was not only freely dispersible in water but also formed nanostructures following 
self-assembly. These nanostructures displayed a suitable particle size, PDI, ZP and 
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morphology for targeted antibiotic therapy. Self-assembly of PEG-FA into NPs was 
confirmed using MD simulations. MST and molecular docking studies confirmed that PEG-
FA did not have any adsorption and binding affinity towards HSA, which indicated its 
potential for preventing bilirubin displacement and reducing side effects. In vitro antibacterial 
study confirmed that conjugation of FA with PEG did not reduce but rather enhanced the 
activity of FA against S. aureus and MRSA. These findings confirmed the potential of the 
self-assembled PEG-FA conjugate as a novel polymer therapeutics to combat multi-drug 
resistant bacteria. In addition, the proposed conjugate can be further explored to encapsulate 
other classes of antibiotics and investigate the synergistic antibacterial effect. 
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CHAPTER 5, CO-AUTHORED PAPERS 
5.1 Introduction  
In addition to the first authored experimental papers in Chapters, 2, 3 and 4 focusing on 
aims 1, 2 and 3, I have also been involved in other papers within our group as a Ph.D. 
student. As these papers also focused on the broad aim of this PhD project to improve 
treatment of bacterial infections, these papers have been included in the thesis. This 
chapter therefore includes one published experimental paper and one review article in an 
ISI International Journals: Colloids and Surfaces B: Biointerfaces (Impact Factor = 3.973) 
and WIREs Nanomedicine & Nanobiotechnology (Impact Factor = 7.689). 
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5.2 Co-authored paper 1 
Self-assembled oleylamine grafted hyaluronic acid polymersomes for delivery of 
vancomycin against methicillin resistant Staphylococcus aureus (MRSA) 
Walvekar, Pavan, Ramesh Gannimani, Mohammed Salih, Sifiso Makhathini, Chunderika 
Mocktar, and Thirumala Govender. Colloids and Surfaces B: Biointerfaces. 2019 Oct 
1;182:110388. (Appendix IV) 
5.2.1 Abstract  
MRSA infections are a major global healthcare problem associated with high morbidity and 
mortality. The application of novel materials in antibiotic delivery has efficiently contributed 
to the treatment of MRSA infections. The study aimed to develop novel hyaluronic acid oleyl 
amine (HA-OLA) conjugates with 25-50% degrees of conjugation, for application as a nano-
drug carrier with inherent antibacterial activity. The biosafety of synthesized novel HA-OLA 
conjugates was confirmed by in vitro cytotoxicity assay. The drug loading ability of HA-
OLA conjugates was confirmed by 26.1-43.12% of vancomycin (VCM) encapsulation in 
self-assembled polymersomes. These polymersomes were dispersed in nano-sized range 
(196.1-360.9 nm) with a negative zeta potential. Vancomycin loaded polymersomes were to 
found have spherical and bilayered morphology. The VCM loaded polymersomes displayed 
sustained drug release for 72 h. In vitro studies showed moderate antibacterial activity for 
HA-OLA conjugates against both S. aureus and MRSA with minimum inhibitory 
concentration (MIC) of 500 μg/mL. The VCM loaded HA-OLA polymersomes displayed 
four-fold lower MIC (1.9 μg/mL) than free VCM (7.8 μg/mL) against MRSA. Furthermore, 
synergism was observed for VCM and HA-OLA against MRSA. Flow cytometry showed 
1.8-fold higher MRSA cell death in the population for VCM loaded polymersomes relative to 
free drug, at concentration of 1.95 μg/mL. Bacterial cell morphology showed that the drug 
loaded polymersomes had stronger impact on MRSA membrane, compared to free VCM. 
These findings suggest that, HA-OLA conjugates are promising nano-carriers to function as 
antibiotic delivery vehicles for the treatment of bacterial/MRSA infections. 
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5.3 Co-authored paper 2 
Intrinsic Stimuli-Responsive Nanocarriers for Smart Drug Delivery of Antibacterial 
Agents – An In-Depth Review of the Last Two Decades 
Nikita Devnarain, Nawras Osman, Victoria Fasiku, Sifiso Makathini, Mohammed Salih, Usri 
Ibrahim and Thirumala Govender. (2020). WIREs Nanomedicine & Nanobiotechnology. 
Manuscript ID: NANOMED-651 (In Press). 
5.3.1 Abstract  
Antibiotic resistance due to suboptimal targeting and inconsistent antibiotic release at 
bacterial infection sites has driven the formulation of stimuli-responsive nanocarriers for 
antibacterial therapy. Unlike conventional nanocarriers, stimuli-responsive nanocarriers have 
the ability to specifically enhance targeting and drug release profiles. There has been a 
significant escalation in the design and development of novel nanomaterials worldwide; in 
particular, intrinsic stimuli-responsive antibiotic nanocarriers, due to their enhanced activity, 
improved targeted delivery and superior potential for bacterial penetration and eradication. 
Herein, we provide an extensive and critical review of pH-, enzyme-, redox- and ionic 
microenvironment-responsive nanocarriers that have been reported in literature to date, with 
an emphasis on the mechanisms of drug release, the nanomaterials used, the nanosystems 
constructed and the antibacterial efficacy of the nanocarriers. The review also highlights 
further avenues of research for optimising their potential and commercialisation. This review 
confirms the potential of intrinsic stimuli-responsive nanocarriers for enhanced drug delivery 
and antibacterial killing.  
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CHAPTER 6, CONCLUSION 
6.1 General conclusions 
Resistance to antibiotics has reached extreme levels throughout the world, with available 
treatment options gradually becoming ineffective to treat MDR bacteria. The development of 
new strategies such as nanotechnology-derived formulations are showing great potential to 
improve the efficacy of existing antibiotics. The severity of bacterial resistance demands new 
materials to develop novel drug delivery systems that can alter the physicochemical 
properties of drugs, and thus, counteract antibacterial resistance and improve the efficiency of 
the drugs. The broad aim of this study was to design advanced materials and explore nano-
based strategies for preparations of self-assembling delivery systems to treat S. aureus and 
MRSA infections. The specific research aims of this study were, therefore to: (1) synthesize 
and formulate a novel supramolecular amphiphile, BCD-OLA, via inclusion complexation for 
the enhancement of VCM delivery; (2) synthesize and formulate a VCM/TS SADDs and 
explore its potential for enhancing the antibacterial activity of VCM against S. aureus and 
MRSA; and (3) to synthesize and formulate a novel PEGylated FA and to explore its 
potential for simultaneously enhancing the solubility and antimicrobial activity of FA and 
lowering its binding to HSA. 
The main conclusions generated from the research data are summarised below:  
Aim 1  
 The supramolecular amphiphile of BCD and OLA was successfully synthesized. FT-
IR, DSC, 
1
H NMR, and 2D NMR analyses confirmed the successful synthesis and 
structure of BCD-OLA amphiphile. 
 A 1:1 stoichiometric inclusion complex was found in the BCD-OLA amphiphile. 
 Cytotoxicity studies performed using the MTT assay on three mammalian cell lines, 
viz; adenocarcinoma alveolar basal epithelial cells (A549), cervical cancer cell-lines 
(HeLa) and human embryonic kidney cells 293 (HEK 293), revealed the BCD-OLA 
amphiphile to be biosafe. 
 The synthesized BCD-OLA amphiphile was employed to formulate VCM loaded 
nanovesicles, which displayed a size of 119.8 ± 1.12 nm with a PDI of 0.220 ± 3.98, 
and ZP of 25.8 ± 6.96 mV, with an encapsulation efficiency of 40.2 ± 4.5%. The 
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VCM release from the drug loaded nanovesicles was found to be sustained, with an 
80% release throughout 48 h.  
 The MD simulations showed spontaneous insertion of OLA into the BCD core and 
formation of stable inclusion complex. Further simulation confirmed the self-
assembly of BCD-OLA amphiphile. 
 The in vitro antibacterial test revealed that the VCM-loaded BCD-OLA nanovesicles 
had 2- and 4-fold lower MIC against S. aureus strains and MRSA respectively, 
compared to the free drug. Furthermore, synergism was observed for VCM and BCD-
OLA against MRSA. 
 The efficacy of the BCD-OLA nanovesicles in eliminating the intracellular MRSA 
was determined by infecting the macrophages (TPH-1) and HEK 293, followed by 
further treatment with the nanovesicles. BCD-OLA nanovesicles showed an 8- and 
459- fold reduction of intracellular bacteria in TPH-1 and HEK 293 infected cells, 
respectively, when compared to bare VCM. 
Aim 2 
 Screening for the proper ratio of complexation between VCM and TS using solvent 
evaporation revealed the preferred ratio to be 1:3 as it displayed the best balance 
between small size, low PDI and the high drug loading capacity. The sizes of the 
formed NPs with the selected ratio were 85.15 ± 0.4 nm, surface charge and drug 
loading were -27 ± 1.3 mV and 68.8 ± 2.8%, respectively. 
 Haemolytic effect and cytotoxicity studies using MTT assay performed on three 
mammalian cell lines MCF-7, A549 and HEK 293, revealed the formulated VCM/TS 
NPs to be non-haemolytic and >75% cell viability was observed, which confirmed 
their biosafety. 
 Molecular dynamics simulation under the same conditions of the experiment, 
confirmed a continued and stable binding between VCM and TS, which was mainly 
governed by hydrophobic interactions, followed by van der Waals and electrostatic 
forces. A further MD simulation of multiple VCM/TS complexes showed 
spontaneous self-aggregation of the complexes. 
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 Structural analysis using FT-IR and DSC showed that only physical binding such as 
hydrophobic interactions contributed to the formation of VCM/TS NPs, without the 
formation of new chemical bonds. 
 The formulated VCM/TS NPs with the selected ratio showed a sustained release of 
VCM from the NPs, with a 52.2% release after 48 h. The in vitro antibacterial test 
showed a 2-fold decrease in MIC against both S. aureus and MRSA, Additionally, it 
was observed that there was a significantly higher reduction in MRSA biofilms 
compared to bare VCM. Further in vivo study using mice skin infection models 
showed a 9.5-fold reduction in bacterial load after treatment with VCM/TS NPs, in 
comparison with bare VCM (p = 0.0077). 
 Molecular dynamics simulations studies showed the potential of TS to stably interact 
with MRSA NorA and NorB efflux pumps at a molecular level, indicating its 
potential as an effective constituent in a delivery system to inhibit efflux pumps for 
enhancing antibacterial activity. 
Aim 3 
 A novel PEGylated FA was successfully synthesized and the structure was confirmed 
by FT-IR, DSC, and 
1
H NMR analysis. 
 Haemolytic effect and cytotoxicity studies using MTT assay was performed on three 
mammalian cell lines MCF-7, HeLa and HEK 293 respectively. Results revealed the 
non-haemolytic effect of the synthesized PEG-FA and >75% cell viability, which 
confirmed its biosafety. 
 The self-assembled PEG-FA NPs displayed an average hydrodynamic diameter of 
149.3 ± 0.21 nm with PDI of 0.267 ± 0.012 and a surface charge of 5.97 ± 1.03 mV. 
HRTEM images revealed a homogenous spherical shape of the PEG-FA NPs. 
 The conjugation of PEG with FA successfully increased the water solubility of FA by 
25-fold. The in vitro antibacterial activity revealed that the conjugation of FA with 
PEG did not inhibit the antibacterial activity of FA but rather enhanced it by 2.5-fold 
against S. aureus and MRSA respectively, compared to the bare FA. 
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 Human serum albumin binding studies using MST showed that PEG-FA had a very 
weak or no interaction with HSA (Kd = 14999 µM). In addition, molecular docking 
revealed that the binding of FA to HSA was more favourable compared to bilirubin, 
while PEG-FA did not fit into the HSA binding pocket. Thus, PEG-FA conjugation 
shows potential in reducing the risk of bilirubin encephalopathy in newborn infants 
due to bilirubin displacement. 
The results of this study, therefore, confirmed the potential of novel BCD-OLA, VCM/TS 
and PEG-FA self-assembling nano-delivery systems to be biosafe and superior in treating S. 
aureus and MRSA infections as compared to the bare antibiotics. The additional 
experimental paper presented in Chapter 5 as a co-author, confirmed the potential of a novel 
self-assembled polymeric conjugate (HA-OLA) for the treatment of bacterial infections. 
Also, the review article in Chapter 5 elucidates the potential of different intrinsic stimuli-
responsive nanocarriers for treatment of bacterial infections. 
6.2 Significance of the findings in the study 
The newly synthesized materials and designed nano formulations comprising; BCD-OLA 
nanovesicles, VCM/TS NPs, and PEG-FA conjugate were successfully employed to address 
the limitations associated with conventional dosage forms of antibiotics and antibacterial 
resistance. The significance of the findings in this study include the following: 
New pharmaceutical products: This study has generated new pharmaceutical materials, viz; 
novel BCD-OLA amphiphile for drug delivery and PEG-FA as a polymer theraputic. Also, a 
new medicine, self-assembled VCM/TS NPs for enhancement of VCM delivery was 
generated. This will expand the range of the available pharmaceutical excipient for preparing 
new medicines, which can stimulate local pharmaceutical industries to manufacture superior 
cost-effective medicines. 
Improved patient therapy and disease treatment: The newly designed BCD-OLA amphiphile, 
VCM/TS NPs, and PEG-FA nanosystems were successfully formulated with improved 
antibacterial potential against S. aureus and MRSA. The novel systems lowered the MIC of 
the loaded drugs and can effectively control bacterial infections with reduced dosing 
frequency without affecting therapeutic outcomes. Additionaly, unlike FA, PEG-FA did not 
have any binding affinity to the HSA, which indicated its potential for preventing bilirubin 
displacement and reducing side effects. These findings, therefore, prove the potential of these 
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systems in improving patient therapy and treatment of bacterial infections, thereby ultimately 
improving the quality of life as well as saving lives. 
Creation of new knowledge to the scientific community: The various studies and their findings 
have contributed to the pharmaceutical sciences knowledge database in several ways. These 
include the following: 
 New knowledge on the synthesis, characterization and determination of the toxicity 
profiles of the supramolecular BCD-OLA complex and PEG-FA conjugate was 
generated. The physicochemical, in vitro, in silico, and in vivo properties of the drug-
loaded BCD-OLA nanovesicles, VCM/TS NPs, and PEG-FA NPs delivery systems 
were identified. 
 Molecular mechanism of the interactions between BCD/OLA and VCM/TS with 
different ratios were identified. The process of spontaneous aggregation of BCD-OLA 
amphiphiles, PEG-FA conjugate and VCM/TS self-assembling complexes in water, 
were successfully confirmed. The ability of TS in the VCM/TS NPs to interact with 
NorA and NorB efflux pumps in MRSA at a molecular level, showed its potential to 
inhibit efflux pumps, which resulted in enhanced antibacterial activity. 
 Formulation and processes parameters for preparation of BCD-OLA nanovesicles, 
VCM/TS NPs and PEG-FA conjugate were identified using various experimental 
techniques. 
 The binding affinity of FA to HSA in comparison to bilirubin and PEG conjugation 
on the binding affinity of FA was quantified using MST. 
 The detailed antimicrobial testing from MIC determination, flow cytometry, time 
killing assay, elimination of intracellular bacteria and in vivo antibacterial infection 
models successfully identified the in vitro and in vivo correlation of the designed and 
formulated nano-drug delivery systems. 
Stimulation of new research: The research findings of the various studies and the successful 
development of BCD-OLA amphiphile, VCM/TS NPs and PEG-FA conjugate can stimulate 
new research areas, including the following:  
 The newly synthesized BCD-OLA can be utilized for delivering other classes of drugs 
to treat various disease conditions, such as cardiovascular diseases, HIV/AIDS, gene 
therapy-related diseases, metabolic diseases amongst others. Also, PEG-FA can be 
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explored to encapsulate other classes of antibiotics and investigate the synergistic 
antibacterial effect. 
 The newly designed carrier-free VCM/TS NPs (SADDs), could stimulate the 
application of this strategy to develop new nano-systems based on hydrophobic 
interaction for delivery other drugs with similar physicochemical properties.  
 The successful formulation and in vitro and in vivo characterization of the reported 
nano-drug delivery systems in this study could stimulate research into the formulation 
of other nano-drug delivery systems for other classes of drugs to treat other diseases.  
 The improved antibacterial activity of FA via polymeric conjugation with PEG and 
self-assembly into NPs, underlines PEGylation as a promising strategy to develop 
novel antibacterial delivery systems to combat the crisis of AMR and enrich the field 
of new antibiotics. 
6.3 Recommendations for future studies  
Although, these approaches have demonstrated the potential of BCD-OLA amphiphile, 
VCM/TS NPs and PEG-FA conjugate as novel nano-drug delivery systems to eradicate the 
problem of bacterial resistance, additional studies are necessary to improve the formulations 
to ensure eventual regulatory approval for patient use.  
The following studies are proposed:  
 In the case of BCD-OLA and PEG-FA, there is a need for coarse-grain MD 
simulations in order to build a system that can completely self-assemble into drug-
loaded nanovesicles and to simulate the release of drug from the system. 
 The successfully developed BCD-OLA nanovesicles for VCM delivery and PEG-FA 
conjugate system can be loaded with different classes of antibiotics. In addition, the 
simultaneous delivery of multiple antibiotics and their ability to achieve enhanced and 
synergistic activities can be explored. 
 The MD simulation studies for interaction between TS and MRSA efflux pumps 
NorA and NorB can be upgraded with a quantitative determination of a specific 
protein using techniques, such as western blot or dot blot analysis. 
 In the case of the VCM/TS NPs, the next phase would be to formulate other 
antibiotics using this simple technique, as well as trying other efflux inhibiting 
molecules that are already FDA-approved and available in the market to enhance the 
antimicrobial activity of other antibiotics further. 
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 Long-term stability studies using international conference of harmonization (ICH) 
conditions to assess the physical and chemical stability of optimized formulations 
must be undertaken to confirm their shelf life.  
 In vivo acute, intermediate and long-term toxicity studies could be performed to 
determine the full toxicological profile of the material and the formulations reported 
in this study.  
 In vivo IV infection model, bioavailability and pharmacokinetic studies, and clinical 
trials could be performed on the developed nano-systems to achieve approval for 
market introduction.  
 Validated scale-up method for production of the nano-systems presented in this study 
could be developed in order to enable their applications in pharmaceutical industries. 
6.4 Conclusion 
The findings of this study specifically demonstrate the potential of the newly developed 
BCD-OLA amphiphile, VCM/TS NPs and PEG-FA conjugates as nano-carriers with inherent 
antibacterial activity, as well as their drug delivery potential, for improving the treatment of 
S. aureus and MRSA infections. This current research has thus, made significant 
contributions to nano-based approaches to overcome limitations of current/conventional 
dosage forms. The study further directed an approach towards the synthesis of novel 
antibacterial amphiphiles to develop multifunctional nano-systems to treat bacterial 
infections. The understanding of novel antibacterial materials and nano-technology in 
addressing the current global antibiotic drug therapy crisis will be dependent on future 
intensive and multidisciplinary research. This approach will play a vital role in improving the 
treatment of diseases associated with bacterial infections, with a tremendous impact on public 
health. 
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APPENDICES 
Appendix I 
Supplementary material for experimental paper One 
 
Figure S1. 
1
H NMR (400 MHz) spectra in CDCl3 at 300 K of OLA.  
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Table S1: FIC index 
Result Synergy Additive Indifference Antagonism 
Index ≤0.5 >0.5 to 1 >1 to <2 ≥2 
 
 
Table S2: Chemical Shifts in ppm of the Protons of BCD, OLA alone and BCD-OLA 
complex from 
1
H NMR (400 MHz). 
δ (ppm) of BCD 
protons 
BCD 
alone 
OLA 
alone 
BCD-OLA 
(1:1) 
Change in chemical 
shift 
H-1 5.111  5.083 -0.028 
H-2 3.6941  3.6657 -0.028 
H-3 4.008  3.932 -0.076 
H-4 3.628  3.6319 0.004 
H-5 3.899  3.7433 -0.156 
H-6 3.926  3.898 -0.028 
a - 5.344 5.481 0.137 
b - 2.615 3.001 0.386 
c - 2.041 2.110 0.069 
d - 1.426 1.685 0.259 
e, f - 1.313 1.342 0.029 
g - 0.929 0.936 0.007 
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Table S3: Average Binding Energy and its components obtained from the MM-PBSA 
Calculation for BCD and OLA complex 
 
R2 = linear regression coefficient, RMSE = Root mean square error. 
 
Table S4: Drug release kinetics data for BCD-OLA/VCM nanovesicles 
 
 
 
 
 
 
 
Table S5: ΣFIC of (BCD-OLA)/VCM for the in vitro antibacterial activity against SA 
and MRSA 
 
  
Model Equation R
2
 RMSE Release exponent (n) β 
First Order Q = Q0 . e
kt
 0.647 13.725 - - 
Higuchi Q = k. t 
½
 0.758 11.372 - - 
Korsmeyer-Peppas Q = k . t
n
 0.943 5.519 0.327 - 
Hixson-Crowell Q
⅓
 = kt + Q0
⅓
 0.492 16.453 - - 
Weibull Q = 1 exp [-(t)a/b] 0.978 4.079 - 0.473 
Contribution  Energy (kJ/mol) 
ΔEvdw -78.59 ± 2.73 
ΔEelec -1.28 ± 0.13 
ΔGpolar  37.46 ± 1.04 
ΔGnonpolar -10.80 ± 0.30 
ΔGtotal -53.25 ± 1.93 
 ΣFIC against SA ΣFIC against MRSA 
(BCD-OLA)/VCM  0.50 (Synergistic) 0.24 (Synergistic) 
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Appendix II 
Supplementary material for experimental paper Two 
Table S1: Size and PDI of different dilutions of VCM/TS NPs in PBS measured using 
Zetasizer. N=3 
VCM/TS NPs Conc 
(µg/ml) 
Size (nm) PDI 
1000 96.12 ± 3.2 0.142 ± 0.11 
100 96.11 ± 2.5 0.174 ± 0.13 
10 97.96 ± 2.1 0.150 ± 0.25 
0.1 520.6 ± 16.2 0.774 ± 4.55 
 
 
Table S2: Haemolysis (%) for different concentrations of VCM/TS NPs, PBS (pH 7.4) and 
distilled water. 
VCM/TS NP 
(mg/ml) 
Haemolysis 
(%) 
0.05 0.08 
0.1 0.07 
0.2 0.30 
0.3 0.41 
0.4 0.58 
0.5 0.78 
PBS (pH 7.4) 0.00 
Distilled water 100.00 
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Figure S1: Homology model of NorA efflux pump (top left) including alignment of NorA 
FASTA sequence with its template (top right). The comparison with nonredundant PDB 
structures (bottom left) and the predicted local similarity to its target (bottom right) are 
shown.   
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Figure 2: Homology model of NorB efflux pump (top left) including alignment of NorB 
FASTA sequence with its template (top right). The comparison with nonredundant PDB 
structures (bottom left) and the predicted local similarity to its target (bottom right) are 
shown. 
 
 
Figure S3: Ramachandran Plots generated from MolProbity for Homology models of NorA 
(A) and NorB (B). 
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Figure S4: Root-mean-square deviation of all systems remained within a stable 2Å range. 
 
 
Figure S5: Radius of gyration of all systems indicating that NorA and NorB proteins expand 
to allow TS to bind more efficiently. 
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Appendix III 
Supplementary material for experimental paper Three 
Method of Synthesis of PEG-FA 
1- Synthesis of (I) 
BOC protection of 6-aminohexanoic acid (6AHA): 
To a stirring solution of 6AHA (0.6 g, 4 mmol) in 25ml methanol, tert-butyl 
decarbonate (1.08 g, 5 mmol) added and the reaction mixture was stirred overnight at 
room temperature. After this time, the solvent was evaporated to complete dryness to 
give a white crude product which was purified by flash chromatography (5 % 
MeOH/CH2Cl2) to yield a crystal white solid (98% yield). 
 
2- Synthesis of (II) 
Conjugation of BOC-6AHA (spacer) to 2000 Polyethylen glycol monoether (PEG): 
PEG-6AHA-BOC was synthesized, by addition of BOC-6AHA (0.462g, 2 mmol) to a 
stirring reaction mixture of PEG 2000 (4g, 2 mmol), DMAP (0.293 g, 2.4 mmol), 
EDC (0.46 g, 2.4 mmol) in dry DCM. The reaction mixture was stirred for 24 h at 
room temperature under inert conditions (N2(g)). After this time, acidic water wash 
was used to removed EDC/DMAP and the organic solvent was evaporated. TLC was 
used to monitor the reaction and complete removal of DMAP, then the product was 
precipitated in cold ether, solid white product product was obtained at Yield above 
80%. 
 
3-  Synthesis of (III) 
Cleaving of BOC: 
To synthesized PEG-6AHA, a reaction mixture of PEG-6AHA-BOC (3.5 g, 1.5 mmol 
) in 25% trifluoroacetic acid (TFA) in DCM was stirred for 2 h at room temperature. 
After this time, TFA was removed under reduced pressure. The traces amount of TFA 
remaining was removed by re-dissolving the crude product in ethyl acetate and 
washed with saturated solution of Na2CO3 and followed by washing with brine 
solution separately. The organic layer was dried over anhydrous MgSO4 to remove 
traces amount of water and filtered off. The solvent was vacuum dried to give the 
final product at yield above 75 %. 
 
4-  Synthesis of (IV) 
Coupling of FA with PEG-6AHA: 
PEG-6AHA-FA was synthesized, by addition of FA (0.591g, 1.1 mmol) to a stirring 
reaction mixture of PEG-6AHA (2.2 g, 1.04 mmol), DMAP (0.152 g, 1.24 mmol), 
EDC (0.239 g, 1.24 mmol) in dry DCM. The reaction mixture was stirred for 24 h at 
room temperature under inert conditions (N2(g)). After this time, acidic water wash 
was used to removed EDC/DMAP and the organic solvent was evaporated. TLC was 
used to monitor the reaction and complete removal of DMAP, then the product was 
precipitated in cold ether, faint yellow product was obtained at Yield above 80%. 
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Figure S1. 
1
H NMR (400 MHz) spectra in CDCl3 of PEG-6AHA 
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Figure S2: IR spectrum of FA, PEG-6AHA, and PEG-FA. 
 
 
Figure S3: The plots for the RMSD, kinetic (EKTOT), potential (EPTOT), and total energy 
(ETOT) for FA-PEG complexes during the MD. 
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Proof of acceptance for experimental paper Three: 
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Proof of acceptance for Co-authored paper 2 
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Appendix V 
Poster for ICONAN 2019 conference, Munich, Germany 
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Appendix VI 
 
